

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Bassam Abdulkarim

1. Abraham A, Sanghera KP, Gheisari F, Koumna S, Riauka T, Ghosh S, Warkentin H, Gabos Z, Chafe S, Tankel K, Huang F, Sabri S, Paterson DI, **Abdulkarim B**, Joseph K. Is Radiation-Induced Cardiac Toxicity Reversible? Prospective Evaluation of Patients With Breast Cancer Enrolled in a Phase 3 Randomized Controlled Trial. *Int J Radiat Oncol Biol Phys.* 2022;113(1):125-3410.1016/j.ijrobp.2022.01.020.
2. Bian DJH, Sabri S, **Abdulkarim BS**. Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. *Cancers (Basel).* 2022;14(15)10.3390/cancers14153598.
3. Daniel P, Meehan B, Sabri S, Jamali F, Sarkaria JN, Choi D, Garnier D, Kitange G, Glennon KI, Paccard A, Karamchandani J, Riazalhosseini Y, Rak J, **Abdulkarim B**. Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. *Neurooncol Adv.* 2022;4(1):vdac07610.1093/oaajnl/vdac076.
4. Khriouan J, Tolba M, Khosrow-Khavar F, Kordlouie S, Guiot MC, **Abdulkarim B**, Shenouda G, Sirhan D, Souhami L, Panet-Raymond V. Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas? *Can J Neurol Sci.* 2022;1-710.1017/cjn.2022.28.

Sharon Abish

1. Castonguay M, Dakhallah N, Desroches J, Colaiacovo ML, Jimenez-Cortes C, Claveau AM, Bérubé S, Hafsaoui AY, Souza A, Tibout P, Ah-Yan C, Vincent AM, Naessens V, Brossard J, **Abish S**, Santiago R, Soulières D, Laroche V, Pastore Y, Tran TH, Forté S. COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic. *J Clin Med.* 2022;11(24)10.3390/jcm11247361.
2. Lim YJ, Arbiv OA, Kalbfleisch ME, Klaassen RJ, Fernandez C, Rayar M, Steele M, Lipton JH, Cuvelier G, Pastore YD, Silva M, Brossard J, Michon B, **Abish S**, Sinha R, Corriveau-Bourque C, Breakey VR, Tole S, Goodyear L, Sung L, Zlateska B, Cada M, Dror Y. Poor outcome after hematopoietic stem cell transplantation of patients with unclassified inherited bone marrow failure syndromes. *Eur J Haematol.* 2022;108(4):278-8710.1111/ejh.13733.

Jason Agulnik

1. **Agulnik JS**, Papadakis AI, Pepe C, Sakr L, Small D, Wang H, Kasymjanova G, Spatz A, Cohen V. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). *Curr Oncol.* 2022;29(2):1107-1610.3390/curroncol29020094.
2. Bierbrier R, D'Aguzzo K, Kasymjanova G, Dell'Aniello S, **Agulnik J**, Pehr K. Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors. *J Am Acad Dermatol.* 202210.1016/j.jaad.2022.10.005.
3. Ezeife DA, Spackman E, Juergens RA, Laskin JJ, **Agulnik JS**, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Melosky B, Shepherd FA, Cohen V, Wheatley-Price P, Vandermeer R, Li JJ, Fernandes R, Shokoohi A, Lanman RB, Leighl NB. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. *Ther Adv Med Oncol.* 2022;14:1758835922111269610.1177/17588359221112696.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

4. Kasymjanova G, Rizzolo A, Pepe C, Friedmann JE, Small D, Spicer J, Lecavalier-Barsoum M, Sultanem K, Wang H, Spatz A, Cohen V, **Agulnik JS**. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol*. 2022;29(11):8677-8510.3390/curroncol29110684.

Moulay Alaoui-Jamali

1. Bijian K, Wernic D, Nivedha AK, Su J, Lim FPL, Miron CE, Amzil H, Moitessier N, **Alaoui-Jamali MA**. Novel Aurora A and Protein Kinase C (α , β 1, β 2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. *J Med Chem*. 2022;65(4):3134-5010.1021/acs.jmedchem.1c01031.
2. Castellano LRC, Cruz S, Hier M, Bonan PRF, **Alaoui-Jamali MA**, da Silva SD. Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2022;14(21)10.3390/cancers14215406.
3. da Silva SD, Morand GB, Diesel L, de Lima JM, Bijian K, Kailasam S, Lefebvre F, Bourque G, Hier M, **Alaoui-Jamali MA**. Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV(600E)-Positive Papillary Thyroid Cancer. *Cells*. 2022;12(1)10.3390/cells12010139.
4. Morand GB, Cardona I, Cruz S, Mlynarek AM, Hier MP, **Alaoui-Jamali MA**, da Silva SD. Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy? *Int J Mol Sci*. 2022;23(15)10.3390/ijms23158395.
5. Morand GB, Diaconescu A, Ibrahim I, Lamarche G, Ruas JS, Dalfen J, Hier MP, **Alaoui-Jamali MA**, Maschietto M, da Silva SD. Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review. *Clin Exp Metastasis*. 2022;39(3):407-1610.1007/s10585-022-10148-9.
6. Yu HG, Bijian K, da Silva SD, Su J, Morand G, Spatz A, **Alaoui-Jamali MA**. NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation. *Oncogene*. 2022;41(21):2984-9910.1038/s41388-022-02317-7.

Joanne Alfieri

1. Faye MD, **Alfieri J**. Advances in Radiation Oncology for the Treatment of Cervical Cancer. *Curr Oncol*. 2022;29(2):928-4410.3390/curroncol29020079.

Raquel Aloyz

1. Fooks K, Galicia-Vazquez G, Gife V, Schcolnik-Cabrera A, Nouhi Z, Poon WWL, Luo V, Rys RN, **Aloyz R**, Orthwein A, Johnson NA, Hulea L, Mercier FE. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. *J Exp Clin Cancer Res*. 2022;41(1):34010.1186/s13046-022-02542-8.

Armen Aprikian

1. **Aprikian A**. The CUA: Advocating for our patients. *Can Urol Assoc J*. 2022;16(10):31510.5489/cuaj.8116.
2. **Aprikian A**. Managing advanced prostate cancer: No longer the primary domain of general urology. *Can Urol Assoc J*. 2022;16(12):38710.5489/cuaj.8196.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

3. **Aprikian A.** Back in the saddle: CUA's return to a live meeting was a huge success! *Can Urol Assoc J.* 2022;16(8):24210.5489/cuaj.8037.
4. Bramhecha YM, Guérard KP, Audet-Walsh É, Rouzbeh S, Kassem O, Pernet E, Scarlata E, Hamel L, Brimo F, Divangahi M, **Aprikian AG**, Chevalier S, Giguère V, Lapointe J. Fatty acid oxidation enzyme Δ^3 , Δ^2 -enoyl-CoA isomerase 1 (ECII) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. *Oncogene.* 2022;41(20):2798-81010.1038/s41388-022-02276-z.
5. Derderian S, Vesval Q, Wissing MD, Hamel L, Côté N, Vanhuysse M, Ferrario C, Bladou F, **Aprikian A**, Chevalier S. Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. *Clin Transl Sci.* 2022;15(11):2597-61210.1111/cts.13372.
6. Hamilton RJ, Canil C, Shrem NS, Kuhathaas K, Jiang MD, Chung P, North S, Czaykowski P, Hotte S, Winquist E, Kollmannsberger C, **Aprikian A**, Soulières D, Tyldesley S, So AI, Power N, Rendon RA, O'Malley M, Wood L, Jewett MAS. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. *Can Urol Assoc J.* 2022;16(6):155-7310.5489/cuaj.7945.
7. Hu J, **Aprikian AG**, Saleh RR, Dragomir A. Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. *Curr Oncol.* 2022;29(11):8626-3710.3390/curroncol29110680.
8. Hu J, **Aprikian AG**, Vanhuysse M, Dragomir A. Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. *Clin Genitourin Cancer.* 2022;20(1):17-2410.1016/j.clgc.2021.08.009.
9. Khriouian J, Patrocinio H, Andonian S, **Aprikian A**, Kassouf W, Tanguay S, Cury FL. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. *Pract Radiat Oncol.* 2022;12(1):e34-e910.1016/j.ppro.2021.07.006.
10. Kokorovic A, So AI, Serag H, French C, Hamilton RJ, IZard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, **Aprikian A**, Rendon RA. UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. *Can Urol Assoc J.* 2022;16(8):E416-e3110.5489/cuaj.8054.
11. Kokorovic A, So AI, Serag H, French C, Hamilton RJ, IZard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, **Aprikian A**, Rendon RA. UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes. *Can Urol Assoc J.* 2022;16(8):243-410.5489/cuaj.8007.
12. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, Rajan R, **Aprikian A**, Tanguay S, Cury FL, Brimo F, Souhami L, Kassouf W. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci.* 2022;36:26-3310.1016/j.euros.2021.11.011.
13. Saad F, **Aprikian A**, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So AI, Usmani N, Vigneault E, Chi KN. 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J.* 2022;16(11):E506-e1510.5489/cuaj.8161.
14. Shrem NS, Wood L, Hamilton RJ, Kuhathaas K, Czaykowski P, Roberts M, Matthew A, IZard JP, Chung P, Nappi L, Jones J, Soulières D, **Aprikian A**, Power N, Canil C. Testicular cancer survivorship: Long-term toxicity and management. *Can Urol Assoc J.* 2022;16(8):257-7210.5489/cuaj.8009.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

15. Thirion DJG, Caissy JA, Poulin F, Lanfranchi CSH, Deda A, **Aprikian A**, Frenette C, Andonian S. Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study. *Antibiotics (Basel)*. 2022;12(1)10.3390/antibiotics12010056.
16. Yanev I, Gatete J, Jr., **Aprikian AG**, Guertin JR, Dragomir A. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context. *Curr Oncol*. 2022;29(5):3393-42410.3390/curroncol29050275.

Jamil Asselah

1. Lessard D, Engler K, Ma Y, Rodriguez Cruz A, Vicente S, Kronfli N, Barkati S, Brouillette MJ, Cox J, Kildea J, Hijal T, Pomey MP, Bartlett SJ, **Asselah J**, Lebouché B. Remote Follow-up of Self-isolating Patients With COVID-19 Using a Patient Portal: Protocol for a Mixed Methods Pilot Study (Opal-COVID Study). *JMIR Res Protoc*. 2022;11(8):e3576010.2196/35760.
2. Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, Guren TK, van Dongen MGJ, Spencer K, Bariani GM, Ascierto PA, Santoro A, Shah M, **Asselah J**, Iqbal S, Takahashi S, Piha-Paul SA, Ott PA, Chatterjee A, Jin F, Norwood K, Delord JP. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. *Lancet Gastroenterol Hepatol*. 2022;7(5):446-5410.1016/s2468-1253(21)00382-4.
3. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, **Asselah J**, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet*. 2022;59(8):793-80010.1136/jmedgenet-2021-108054.

Laurent Azoulay

1. Yap TA, Jacobs I, Baumfeld Andre E, Lee LJ, Beaupre D, **Azoulay L**. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. *Front Oncol*. 2021;11:69593610.3389/fonc.2021.695936.
2. Abenhaim HA, Suissa S, **Azoulay L**, Spence AR, Czuzoj-Shulman N, Tulandi T. Menopausal Hormone Therapy Formulation and Breast Cancer Risk. *Obstet Gynecol*. 2022;139(6):1103-1010.1097/aog.0000000000004723.
3. Abrahimi D, **Azoulay L**. Response by Abrahimi et al to letter regarding article 'Proton pump inhibitors and risk of colorectal cancer'. *Gut*. 2022;71(8):1690-110.1136/gutjnl-2021-326544.
4. Abrahimi D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, **Azoulay L**. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. *Gut*. 2022;71(1):16-2410.1136/gutjnl-2021-325097.
5. Abrahimi D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, **Azoulay L**. Proton pump inhibitors and risk of colorectal cancer. *Gut*. 2022;71(1):111-810.1136/gutjnl-2021-325096.
6. Abrahimi D, Tesfaye H, Yin H, Vine S, Hicks B, Yu OHY, Campeau L, Platt RW, Schneeweiss S, Paterno E, **Azoulay L**. Sodium-Glucose Cotransporter 2 Inhibitors and the

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

- Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. *Diabetes Care*. 2022;45(12):2907-1710.2337/dc22-1174.
7. **Azoulay L**. Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective. *Oncologist*. 2022;27(9):e731-e810.1093/oncolo/oyac114.
 8. Cao TXD, Filliter C, Montastruc F, Yu OHY, Fergusson E, Rej S, **Azoulay L**, Renoux C. Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. *J Affect Disord*. 2022;318:231-710.1016/j.jad.2022.08.094.
 9. Chowdhury KR, Michaud J, Yu OHY, Yin H, **Azoulay L**, Renoux C. Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus. *Thromb Haemost*. 2022;122(10):1794-80310.1055/a-1798-2116.
 10. Darwish I, Harrison LB, Passos-Castilho AM, Labbé AC, Barkati S, Luong ML, Kong LY, Tutt-Guérrette MA, Kierans J, Rousseau C, Benedetti A, **Azoulay L**, Greenaway C. In-hospital outcomes of SARS-CoV-2-infected health care workers in the COVID-19 pandemic first wave, Quebec, Canada. *PLoS One*. 2022;17(8):e027295310.1371/journal.pone.0272953.
 11. Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, **Azoulay L**. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. *Clin Pharmacol Ther*. 2022;111(1):272-8210.1002/cpt.2430.
 12. Khosrow-Khavar F, **Azoulay L**, Montastruc JL, Montastruc F, Renoux C. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study. *Cancer*. 2022;128(12):2339-4710.1002/cncr.34208.
 13. Kuramoto LK, Sobolev BG, Rosner J, Brasher PMA, **Azoulay L**, Cragg JJ. A systematic, concept-based method of developing the exposure measure for drug safety and effectiveness studies. *Pharmacoepidemiol Drug Saf*. 2022;31(1):13-2110.1002/pds.5372.
 14. Lu S, Yin H, Yu OHY, **Azoulay L**. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes. *Epidemiology*. 2022;33(4):563-7110.1097/ede.0000000000001486.
 15. Ou LB, **Azoulay L**, Reynier P, Platt RW, Yoon S, Grad R, Filion KB. Tramadol versus codeine and the short-term risk of cardiovascular events in patients with non-cancer pain: A population-based cohort study. *Br J Clin Pharmacol*. 2022;88(4):1824-3410.1111/bcp.15099.
 16. Passos-Castilho AM, Labbé AC, Barkati S, Luong ML, Dagher O, Maynard N, Tutt-Guérrette MA, Kierans J, Rousseau C, Benedetti A, **Azoulay L**, Greenaway C. Outcomes of hospitalized COVID-19 patients in Canada: impact of ethnicity, migration status and country of birth. *J Travel Med*. 2022;29(6)10.1093/jtm/taac041.
 17. Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S, **Azoulay L**. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. *Bmj*. 2022;379:e07138010.1136/bmj-2022-071380.
 18. Pradhan R, Patorno E, **Azoulay L**. Pradhan et al. Respond to "Large-Scale, Multisite Studies Using Real-World Data". *Am J Epidemiol*. 2022;191(8):1372-310.1093/aje/kwac097.
 19. Pradhan R, Patorno E, Tesfaye H, Schneeweiss S, Yin H, Franklin J, Pawar A, Santella C, Yu OHY, Renoux C, **Azoulay L**. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study. *Am J Epidemiol*. 2022;191(8):1352-6710.1093/aje/kwac021.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

20. Pradhan R, Yin H, Yu O, **Azoulay L**. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. *Diabetes Care*. 2022;45(4):819-2910.2337/dc21-1953.
21. Pradhan R, Yin H, Yu OHY, **Azoulay L**. Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes. *Diabetes Care*. 2022;45(10):2289-9810.2337/dc22-0712.
22. Pradhan R, Yu O, Platt RW, **Azoulay L**. Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. *Diabetes Res Clin Pract*. 2022;185:10922910.1016/j.diabres.2022.109229.
23. Rouette J, McDonald EG, Schuster T, Brophy JM, **Azoulay L**. Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study. *J Am Heart Assoc*. 2022;11(24):e02678910.1161/jaha.122.026789.
24. Rouette J, McDonald EG, Schuster T, Brophy JM, **Azoulay L**. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. *BMJ Open*. 2022;12(6):e05751010.1136/bmjopen-2021-057510.
25. Rouette J, Yin H, McDonald EG, Barkun A, **Azoulay L**. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. *Drug Saf*. 2022;45(1):65-7410.1007/s40264-021-01128-1.
26. Subramanian A, Han D, Braithwaite T, Thayakaran R, Zemedikun DT, Gokhale KM, Lee WH, Coker J, Keane PA, Denniston AK, Nirantharakumar K, **Azoulay L**, Adderley NJ. Angiotensin-converting enzyme inhibitors and risk of age-related macular degeneration in individuals with hypertension. *Br J Clin Pharmacol*. 2022;88(9):4199-21010.1111/bcp.15366.
27. Suissa K, Schneeweiss S, Douros A, Yin H, Paterno E, **Azoulay L**. Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. *Diabetes Res Clin Pract*. 2022;192:11009410.1016/j.diabres.2022.110094.

Boris Bahoric

1. Di Lalla V, Elakshar S, Anidjar M, Tolba M, Hassan T, **Bahoric B**, McPherson V, Probst S, Niazi T. Salvage external beam radiotherapy after HIFU failure in localized prostate cancer: A single institution experience. *Front Oncol*. 2022;12:102885810.3389/fonc.2022.1028858.
2. Tisseverasinghe S, Tolba M, Saad F, Gravis G, **Bahoric B**, Niazi T. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? *J Clin Oncol*. 2022;40(36):4173-710.1200/jco.22.00883.
3. Maliha PG, Nolet B, Ebrahim A, Abikhzer G, Chaussé G, **Bahoric B**, Niazi T, Probst S. Comparing digital to analog prostate-specific membrane antigen-targeted piflufolostat 18 F PET/CT in prostate cancer patients in early biochemical failure. *Nucl Med Commun*. 2023;44(3):187-9310.1097/mnm.0000000000001652.

Mark Basik

1. Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- RM, Sahin O, Bareke E, St-Pierre J, Park M, **Basik M**, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. *Oncogene*. 2022;41(12):1701-1710.1038/s41388-022-02206-z.
2. Cambrosio A, Campbell J, Keating P, Polk JB, Aguilar-Mahecha A, **Basik M**. Healthcare policy by other means: Cancer clinical research as "oncopolicy". *Soc Sci Med*. 2022;292:11457610.1016/j.socscimed.2021.114576.
 3. Eisenberg ER, Weiss A, Prakash I, Skamene S, **Basik M**, Boileau JF, Ajjamada L, Pollak MN, Wong SM. Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. *Ann Surg Oncol*. 2022;29(11):6673-8010.1245/s10434-022-11947-w.
 4. Khan SA, Zhao F, Goldstein LJ, Cella D, **Basik M**, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). *J Clin Oncol*. 2022;40(9):978-8710.1200/jco.21.02006.
 5. Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, Park M, **Basik M**, Witcher M. 3D chromatin remodeling potentiates transcriptional programs driving cell invasion. *Proc Natl Acad Sci U S A*. 2022;119(36):e220345211910.1073/pnas.2203452119.
 6. Mitsa G, Guo Q, Goncalves C, Preston SEJ, Lacasse V, Aguilar-Mahecha A, Benlimame N, **Basik M**, Spatz A, Batist G, Miller WH, Jr., Del Rincon SV, Zahedi RP, Borchers CH. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. *Int J Mol Sci*. 2022;23(8)10.3390/ijms23084443.
 7. Shickh S, Oldfield LE, Clausen M, Mighton C, Sebastian A, Calvo A, Baxter NN, Dawson L, Penney LS, Foulkes W, **Basik M**, Sun S, Schrader KA, Regier DA, Karsan A, Pollett A, Pugh TJ, Kim RH, Bombard Y. "Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. *Oncologist*. 2022;27(5):e393-e40110.1093/oncolo/oyac039.
 8. Wong SM, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, Pollak MN, **Basik M**. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer*. 2022;128(7):1365-7210.1002/cncr.34065.
 9. Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, **Basik M**, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD. ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol*. 2022;29(11):6671-210.1245/s10434-022-12011-3.
 10. Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, **Basik M**, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol*. 2022;29(11):6660-810.1245/s10434-022-11916-3.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Gerald Batist

1. Elkrif A, Hennessy C, Kuderer NM, Rubinstein SM, Wulff-Burchfield E, Rosovsky RP, Vega-Luna K, Thompson MA, Panagiotou OA, Desai A, Rivera DR, Khaki AR, Tachiki L, Lynch RC, Stratton C, Elias R, **Batist G**, Kasi A, Shah DP, Bakouny Z, Cabal A, Clement J, Crowell J, Dixon B, Friese CR, Fry SL, Grover P, Gulati S, Gupta S, Hwang C, Khan H, Kim SJ, Klein EJ, Labaki C, McKay RR, Nizam A, Pennell NA, Puc M, Schmidt AL, Shahrokni A, Shaya JA, Su CT, Wall S, Williams N, Wise-Draper TM, Mishra S, Grivas P, French B, Warner JL, Wildes TM. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. *Lancet Healthy Longev.* 2022;3(3):e143-e5210.1016/s2666-7568(22)00009-5.
2. Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Taberero J, **Batist G**, Spatz A, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. *JCO Precis Oncol.* 2022;6:e220007210.1200/po.22.00072.
3. Lazar V, Raynaud J, Magidi S, Bresson C, Martini JF, Galbraith S, Wunder F, Onn A, **Batist G**, Girard N, Lassen U, Pramesh CS, Al-Omari A, Ikeda S, Berchem G, Blay JY, Solomon B, Felip E, Taberero J, Rubin E, Philip T, Porgador A, Berindan-Neagoe I, Schilsky RL, Kurzrock R. Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. *Ther Adv Med Oncol.* 2022;14:1758835922113389310.1177/17588359221133893.
4. Mitsa G, Guo Q, Goncalves C, Preston SEJ, Lacasse V, Aguilar-Mahecha A, Benlimame N, Basik M, Spatz A, **Batist G**, Miller WH, Jr., Del Rincon SV, Zahedi RP, Borchers CH. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. *Int J Mol Sci.* 2022;23(8)10.3390/ijms23084443.
5. Sobsey CA, Froehlich B, **Batist G**, Borchers CH. Immuno-MALDI-MS for Accurate Quantitation of Targeted Peptides from Volume-Restricted Samples. *Methods Mol Biol.* 2022;2515:203-2510.1007/978-1-0716-2409-8_13.
6. Stewart DJ, Bradford JP, **Batist G**. Treatment Access, Health Economics, and the Wave of a Magic Wand. *Curr Oncol.* 2022;29(2):1176-8910.3390/curroncol29020100.

Christoph Borchers

1. Brzhozovskiy A, Kononikhin A, Bugrova AE, Kovalev GI, Schmit PO, Kruppa G, Nikolaev EN, **Borchers CH**. The Parallel Reaction Monitoring-Parallel Accumulation-Serial Fragmentation (prm-PASEF) Approach for Multiplexed Absolute Quantitation of Proteins in Human Plasma. *Anal Chem.* 2022;94(4):2016-2210.1021/acs.analchem.1c03782.
2. Gaither C, Popp R, Zahedi RP, **Borchers CH**. Multiple Reaction Monitoring-Mass Spectrometry Enables Robust Quantitation of Plasma Proteins Regardless of Whole Blood Processing Delays That May Occur in the Clinic. *Mol Cell Proteomics.* 2022;21(5):10021210.1016/j.mcpro.2022.100212.
3. Jennings MJ, Kagiava A, Vendredy L, Spaulding EL, Stavrou M, Hathazi D, Grüneboom A, De Winter V, Gess B, Schara U, Pogoryelova O, Lochmüller H, **Borchers CH**, Roos A, Burgess RW, Timmerman V, Kleopa KA, Horvath R. NCAM1 and GDF15 are biomarkers

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- of Charcot-Marie-Tooth disease in patients and mice. *Brain*. 2022;145(11):3999-401510.1093/brain/awac055.
4. Laselva O, Petrotchenko EV, Hamilton CM, Qureshi Z, **Borchers CH**, Young RN, Bear CE. A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein. *STAR Protoc*. 2022;3(2):10125810.1016/j.xpro.2022.101258.
 5. Mitsa G, Guo Q, Goncalves C, Preston SEJ, Lacasse V, Aguilar-Mahecha A, Benlimame N, Basik M, Spatz A, Batist G, Miller WH, Jr., Del Rincon SV, Zahedi RP, **Borchers CH**. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. *Int J Mol Sci*. 2022;23(8)10.3390/ijms23084443.
 6. Mohammed Y, Touw CE, Nemeth B, van Adrichem RA, **Borchers CH**, Rosendaal FR, van Vlijmen BJ, Cannegieter SC. Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy. *J Thromb Haemost*. 2022;20(3):684-9910.1111/jth.15623.
 7. Parra ALC, Freitas CDT, Souza PFN, von Aderkas P, **Borchers CH**, Beattie GA, Silva FDA, Thornburg RW. Ornamental tobacco floral nectar is a rich source of antimicrobial peptides. *Plant Sci*. 2022;324:11142710.1016/j.plantsci.2022.111427.
 8. Pastushkova LK, Goncharov IN, Koloteva MI, Goncharova AG, Kashirina DN, Nosovsky AM, Glebova TM, Kononikhin AS, **Borchers CH**, Nikolaev EN, Larina IM. Characteristics of blood plasma proteome changes associated with the hemorrhagic purpura of cosmonauts on the first day after long-term space missions. *Life Sci Space Res (Amst)*. 2022;33:7-1210.1016/j.lssr.2022.01.001.
 9. Petrotchenko EV, **Borchers CH**. Protein Chemistry Combined with Mass Spectrometry for Protein Structure Determination. *Chem Rev*. 2022;122(8):7488-9910.1021/acs.chemrev.1c00302.
 10. Preston SEJ, Bartish M, Richard VR, Aghigh A, Gonçalves C, Smith-Voudouris J, Huang F, Thébault P, Cleret-Buhot A, Lapointe R, Légaré F, Postovit LM, Zahedi RP, **Borchers CH**, Miller WH, Jr., Del Rincón SV. Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland. *Matrix Biol*. 2022;111:264-8810.1016/j.matbio.2022.07.003.
 11. Richard VR, Gaither C, Popp R, Chaplygina D, Brzhozovskiy A, Kononikhin A, Mohammed Y, Zahedi RP, Nikolaev EN, **Borchers CH**. Early Prediction of COVID-19 Patient Survival by Targeted Plasma Multi-Omics and Machine Learning. *Mol Cell Proteomics*. 2022;21(10):10027710.1016/j.mcpro.2022.100277.
 12. Sobsey CA, Froehlich B, Batist G, **Borchers CH**. Immuno-MALDI-MS for Accurate Quantitation of Targeted Peptides from Volume-Restricted Samples. *Methods Mol Biol*. 2022;2515:203-2510.1007/978-1-0716-2409-8_13.

Sylvie Bouchard

1. Belayneh M, Fainsinger R, Nekolaichuk C, Muller V, **Bouchard S**, Downar J, Galloway L, Ghosh S, Hawley P, Herx L, Kmet A, Lawlor P. Edmonton Classification System for Cancer Pain: Comparison of Pain Classification Features and Pain Intensity across Diverse Palliative Care Settings in Canada. *J Palliat Med*. 202210.1089/jpm.2022.0187.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Pnina Brodt

1. Latacz E, Höppener D, Bohlok A, Leduc S, Tabariès S, Fernández Moro C, Lugassy C, Nyström H, Bozóky B, Floris G, Geyer N, **Brodt P**, Llado L, Van Mileghem L, De Schepper M, Majeed AW, Lazaris A, Dirix P, Zhang Q, Petrillo SK, Vankerckhove S, Joye I, Meyer Y, Gregorieff A, Roig NR, Vidal-Vanaclocha F, Denis L, Oliveira RC, Metrakos P, Grünhagen DJ, Nagtegaal ID, Mollevi DG, Jarnagin WR, D'Angelica MI, Reynolds AR, Doukas M, Desmedt C, Dirix L, Donckier V, Siegel PM, Barnhill R, Gerling M, Verhoef C, Vermeulen PB. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. *Br J Cancer*. 2022;127(6):988-101310.1038/s41416-022-01859-7.

Julia Burnier

1. Abdouh M, Lu M, Chen Y, Goyeneche A, **Burnier JV**, Burnier MN, Jr. Filtering blue light mitigates the deleterious effects induced by the oxidative stress in human retinal pigment epithelial cells. *Exp Eye Res*. 2022;217:10897810.1016/j.exer.2022.108978.
2. Pessuti CL, Costa DF, Ribeiro KS, Abdouh M, Tsering T, Nascimento H, Commodaro AG, Marcos AAA, Torrecilhas AC, Belfort RN, Belfort R, Jr., **Burnier JV**. Characterization of extracellular vesicles isolated from different liquid biopsies of uveal melanoma patients. *J Circ Biomark*. 2022;11:36-4710.33393/jcb.2022.2370.
3. Tsering T, Li M, Chen Y, Nadeau A, Laskaris A, Abdouh M, Bustamante P, **Burnier JV**. EV-ADD, a database for EV-associated DNA in human liquid biopsy samples. *J Extracell Vesicles*. 2022;11(10):e1227010.1002/jev2.12270.

Prosanto Chaudhury

1. Alghamdi A, Palmieri V, Alotaibi N, Barkun A, Zogopoulos G, **Chaudhury P**, Barkun J, Miller C, Benmassaoud A, Parent J, Martel M, Chen YI. Preoperative Endoscopic Ultrasound Fine Needle Aspiration Versus Upfront Surgery in Resectable Pancreatic Cancer: A Systematic Review and Meta-analysis of Clinical Outcomes Including Survival and Risk of Tumor Recurrence. *J Can Assoc Gastroenterol*. 2022;5(3):121-810.1093/jcag/gwab037.
2. Chen YI, Chatterjee A, Berger R, Kanber Y, Wyse J, Lam E, Gan I, Auger M, Kenshil S, Telford J, Donnellan F, Quinlan J, Lutzak G, Alshamsi F, Parent J, Waschke K, Alghamdi A, Barkun J, Metrakos P, **Chaudhury P**, Martel M, Dorreen A, Candido K, Miller C, Adam V, Barkun A, Zogopoulos G, Wong C. Endoscopic ultrasound (EUS)-guided fine needle biopsy alone vs. EUS-guided fine needle aspiration with rapid onsite evaluation in pancreatic lesions: a multicenter randomized trial. *Endoscopy*. 2022;54(1):4-1210.1055/a-1375-9775.
3. Do U, El-Kefraoui C, Pook M, Balvardi S, Barone N, Nguyen-Powanda P, Lee L, Baldini G, Feldman LS, Fiore JF, Jr., Alhashemi M, Antoun A, Barkun JS, Brecht KM, **Chaudhury PK**, Deckelbaum D, Di Lena E, Dumitra S, Elhaj H, Fata P, Fleiszer D, Fried GM, Grushka J, Kaneva P, Khwaja K, Lapointe-Gagner M, McKendy KM, Meguerditchian AN, Meterissian SH, Montgomery H, Rajabiyazdi F, Safa N, Touma N, Tremblay F. Feasibility of Prospectively Comparing Opioid Analgesia With Opioid-Free Analgesia After Outpatient General Surgery: A Pilot Randomized Clinical Trial. *JAMA Netw Open*. 2022;5(7):e222143010.1001/jamanetworkopen.2022.21430.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

4. Karanicolos PJ, Lin Y, McCluskey S, Roke R, Tarshis J, Thorpe KE, Ball CG, **Chaudhury P**, Cleary SP, Dixon E, Eeson G, Moulton CA, Nanji S, Porter G, Ruo L, Skaro AI, Tsang M, Wei AC, Guyatt G. Tranexamic acid versus placebo to reduce perioperative blood transfusion in patients undergoing liver resection: protocol for the haemorrhage during liver resection tranexamic acid (HeLiX) randomised controlled trial. *BMJ Open*. 2022;12(2):e05885010.1136/bmjopen-2021-058850.
5. Marino A, Bessissow A, Miller C, Valenti D, Boucher L, **Chaudhury P**, Barkun J, Forbes N, Khashab MA, Martel M, Chen YI. Modified endoscopic ultrasound-guided double-balloon-occluded gastroenterostomy bypass (M-EPASS): a pilot study. *Endoscopy*. 2022;54(2):170-210.1055/a-1392-4546.
6. Wang Y, Golesworthy B, Cuggia A, Domecq C, **Chaudhury P**, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet*. 2022;59(8):793-80010.1136/jmedgenet-2021-108054.

Victor Cohen

1. Agulnik JS, Papadakis AI, Pepe C, Sakr L, Small D, Wang H, Kasymjanova G, Spatz A, **Cohen V**. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). *Curr Oncol*. 2022;29(2):1107-1610.3390/curroncol29020094.
2. Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Melosky B, Shepherd FA, **Cohen V**, Wheatley-Price P, Vandermeer R, Li JJ, Fernandes R, Shokoohi A, Lanman RB, Leighl NB. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. *Ther Adv Med Oncol*. 2022;14:1758835922111269610.1177/17588359221112696.
3. Kasymjanova G, Rizzolo A, Pepe C, Friedmann JE, Small D, Spicer J, Lecavalier-Barsoum M, Sultanem K, Wang H, Spatz A, **Cohen V**, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol*. 2022;29(11):8677-8510.3390/curroncol29110684.

Fabio Cury

1. Albert JG, Lo C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Sultanem K, Shenouda G, **Cury FL**, Henry M. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol*. 2022;29(7):4438-5410.3390/curroncol29070353.
2. Almarzouq A, Kool R, Al Bulushi Y, Marcq G, Souhami L, **Cury FL**, Brimo F, Chong J, Kassouf W. Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. *Urol Oncol*. 2022;40(5):194.e15-.e2210.1016/j.urolonc.2021.11.002.
3. Khriguian J, Patrocinio H, Andonian S, Aprikian A, Kassouf W, Tanguay S, **Cury FL**. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. *Pract Radiat Oncol*. 2022;12(1):e34-e910.1016/j.prro.2021.07.006.
4. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, Rajan R, Aprikian A, Tanguay S, **Cury FL**, Brimo F, Souhami L, Kassouf W. Role of Serum Lymphocyte-derived

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

- Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci.* 2022;36:26-3310.1016/j.euros.2021.11.011.
5. Kool R, Yanev I, Hijal T, Vanhuysse M, **Cury FL**, Souhami L, Kassouf W, Dragomir A. Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. *Can Urol Assoc J.* 2022;16(6):189-9810.5489/cuaj.7430.
 6. Marcq G, Evaristo G, Kool R, Shinde-Jadhav S, Skowronski R, Mansure JJ, Souhami L, **Cury F**, Brimo F, Kassouf W. Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. *Eur Urol Open Sci.* 2022;43:14-2110.1016/j.euros.2022.06.009.
 7. Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, **Cury FL**, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). *Lancet Oncol.* 2022;23(12):1508-1610.1016/s1470-2045(22)00656-8.
 8. Viani GA, Gouveia AG, Moraes FY, **Cury FL**. Meta-analysis of Elective Pelvic Nodal Irradiation Using Moderate Hypofractionation for High-Risk Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2022;113(5):1044-5310.1016/j.ijrobp.2022.04.008.

Marc David

1. Naseri H, Skamene S, Tolba M, Faye MD, Ramia P, Khriugian J, Patrick H, Andrade Hernandez AX, **David M**, Kildea J. Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest. *Sci Rep.* 2022;12(1):986610.1038/s41598-022-13379-8.

Sonia del Rincón

1. Dahabieh MS, Huang F, Goncalves C, Flores González RE, Prabhu S, Bolt A, Di Pietro E, Houry E, Heath J, Xu ZY, Rémy-Sarrazin J, Mann KK, Orthwein A, Boisvert FM, Braverman N, Miller WH, **Del Rincón SV**. Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance. *Autophagy.* 2022;18(3):540-5810.1080/15548627.2021.1936932.
2. Henderson Berg MH, Del Rincón SV, Miller WH. Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. *J Immunother Cancer.* 2022;10(1)10.1136/jitc-2021-003551.
3. Mitsa G, Guo Q, Goncalves C, Preston SEJ, Lacasse V, Aguilar-Mahecha A, Benlimame N, Basik M, Spatz A, Batist G, Miller WH, Jr., **Del Rincon SV**, Zahedi RP, Borchers CH. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. *Int J Mol Sci.* 2022;23(8)10.3390/ijms23084443.
4. Moldoveanu D, Ramsay L, Lajoie M, Anderson-Trocme L, Lingrand M, Berry D, Perus LJM, Wei Y, Moraes C, Alkallas R, Rajkumar S, Zuo D, Dankner M, Xu EH, Bertos NR, Najafabadi HS, Gravel S, Costantino S, Richer MJ, Lund AW, **Del Rincon SV**, Spatz A, Miller WH, Jr., Jamal R, Lapointe R, Mes-Masson AM, Turcotte S, Petrecca K, Dumitra S, Meguerditchian AN, Richardson K, Tremblay F, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Quail DF, Mihalcioiu C, Meterissian S, Watson IR. Spatially mapping the

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- immune landscape of melanoma using imaging mass cytometry. *Sci Immunol.* 2022;7(70):eabi507210.1126/sciimmunol.abi5072.
5. Preston SEJ, Bartish M, Richard VR, Aghigh A, Gonçalves C, Smith-Voudouris J, Huang F, Thébault P, Cleret-Buhot A, Lapointe R, Légaré F, Postovit LM, Zahedi RP, Borchers CH, Miller WH, Jr., **Del Rincón SV**. Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland. *Matrix Biol.* 2022;111:264-8810.1016/j.matbio.2022.07.003.
 6. Preston SEJ, Emond A, Pettersson F, Dupéré-Richer D, Abraham MJ, Riva A, Kinal M, Rys RN, Johnson NA, Mann KK, **Del Rincón SV**, Licht JD, Miller WH. Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. *Mol Cancer Ther.* 2022;21(4):511-2110.1158/1535-7163.Mct-21-0216.
 7. Simo Cheyou E, Boni J, Boulais J, Pinedo-Carpio E, Malina A, Sherill-Rofe D, Luo VM, Goncalves C, Bagci H, Maters A, Cuella-Martin R, Tabach Y, **Del Rincon S**, Côté JF, Rivera B, Orthwein A. Systematic proximal mapping of the classical RAD51 paralogs unravel functionally and clinically relevant interactors for genome stability. *PLoS Genet.* 2022;18(11):e101049510.1371/journal.pgen.1010495.
 8. Srouf N, Villarreal OD, Hardikar S, Yu Z, Preston S, Miller WH, Jr., Szewczyk MM, Barsyte-Lovejoy D, Xu H, Chen T, **Del Rincón SV**, Richard S. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. *Cell Rep.* 2022;38(13):11058210.1016/j.celrep.2022.110582.

Slobodan Devic

1. Garant A, Vasilevsky CA, Boutros M, Khosrow-Khavar F, Kavan P, Diec H, Des Groseilliers S, Faria J, Ferland E, Pelsser V, Martin AG, **Devic S**, Vuong T. MORPHEUS Phase II-III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results. *Cancers (Basel).* 2022;14(15)10.3390/cancers14153665.
2. Vuong T, Garant A, Vendrely V, Nout R, Martin AG, Enger SA, Podgorsak E, Moftah B, **Devic S**. Image-Guided Brachytherapy for Rectal Cancer: Reviewing the Past Two Decades of Clinical Investigation. *Cancers (Basel).* 2022;14(19)10.3390/cancers14194846.

Shirin Enger

1. Carroll L, **Enger SA**. Simulation of a novel, non-invasive radiation detector to measure the arterial input function for dynamic positron emission tomography. *Med Phys.* 202210.1002/mp.16055.
2. Rodrigues-Machado FC, Pestre P, Dumont V, Bernard S, Janitz E, Scanlon L, **Enger SA**, Childress L, Sankey J. Sideband cavity absorption readout (SideCAR) with a robust frequency lock. *Opt Express.* 2022;30(2):754-6710.1364/oe.443109.
3. Vuong T, Garant A, Vendrely V, Nout R, Martin AG, **Enger SA**, Podgorsak E, Moftah B, Devic S. Image-Guided Brachytherapy for Rectal Cancer: Reviewing the Past Two Decades of Clinical Investigation. *Cancers (Basel).* 2022;14(19)10.3390/cancers14194846.
4. Weishaupt LL, Sayed HK, Mao X, Choo R, Stish BJ, **Enger SA**, Deufel C. Approaching automated applicator digitization from a new angle: Using sagittal images to improve deep learning accuracy and robustness in high-dose-rate prostate brachytherapy. *Brachytherapy.* 2022;21(4):520-3110.1016/j.brachy.2022.02.005.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Khashayar Esfahani

1. Bierbrier R, **Esfahani K**, Pehr K. Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors. *J Cutan Med Surg*. 2022;26(6):624-510.1177/12034754221119497.
2. Filimon S, Pop C, Chetrit M, **Esfahani K**, Hudson M, Rouleau J, Thanassoulis G, O'Meara E, Bouabdallaoui N, Michel C, Aziz H, Gold P, Tardif JC, Huynh T. A New Era: Immunotherapy Applied to Contemporary Cardiovascular Practice. *Can J Cardiol*. 2022;38(10):1629-3310.1016/j.cjca.2022.05.013.
3. Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR, Tachiki L, Nakasone ES, Loggers ET, Labaki C, Saliby RM, McKay RR, Ajmera A, Griffiths EA, Puzanov I, Tap WD, Hwang C, Tejwani S, Jhawar SR, Hayes-Lattin B, Wulff-Burchfield E, Kasi A, Reuben DY, Nagaraj G, Joshi M, Polimera H, Kulkarni AA, **Esfahani K**, Kwon DH, Paoluzzi L, Bilen MA, Durbin EB, Grivas P, Warner JL, Davis EJ. Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. *Cancers (Basel)*. 2022;14(17)10.3390/cancers14174334.

Marc Fabian

1. Brothers WR, Fakim H, Kajjo S, **Fabian MR**. P-bodies directly regulate MARF1-mediated mRNA decay in human cells. *Nucleic Acids Res*. 2022;50(13):7623-3610.1093/nar/gkac557.
2. Kajjo S, Sharma S, Chen S, Brothers WR, Cott M, Hasaj B, Jovanovic P, Larsson O, **Fabian MR**. PABP prevents the untimely decay of select mRNA populations in human cells. *Embo j*. 2022;41(6):e10865010.15252/embj.2021108650.

Sergio Faria

1. Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, **Faria SL**, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. *Lancet*. 2022;399(10338):1886-90110.1016/s0140-6736(21)01790-6.
2. Swaminath A, Wierzbicki M, Parpia S, Kundapur V, **Faria S**, Ahmed N, Bujold A, Hirmiz K, Owen T, Leong N, Ramchandrar K, Filion E, Lau H, Thompson R, Yaremko B, Gabos Z, Mehiri S, Wright JR, Tsakiridis TK, Cline K, Whelan TJ. Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial. *Clin Transl Radiat Oncol*. 2022;37:145-5210.1016/j.ctro.2022.10.002.

Cristiano Ferrario

1. Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *N Engl J Med*. 2022;387(3):217-2610.1056/NEJMoa2202809.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

2. Derderian S, Vesval Q, Wissing MD, Hamel L, Côté N, Vanhuyse M, **Ferrario C**, Bladou F, Aprikian A, Chevalier S. Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. *Clin Transl Sci.* 2022;15(11):2597-61210.1111/cts.13372.
3. **Ferrario C**, Christofides A, Joy AA, Laing K, Gelmon K, Brezden-Masley C. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. *Curr Oncol.* 2022;29(4):2720-3410.3390/curroncol29040222.
4. Geyer CE, Jr., Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delalogue S, Domchek SM, Eisen A, Elsayf F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson Ó, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martínez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol.* 2022;33(12):1250-6810.1016/j.annonc.2022.09.159.
5. Liu RF, Juwara L, **Ferrario C**, Probst SM. Outcomes and Factors Associated with Completion of Radium-223 Therapy. *Nucl Med Mol Imaging.* 2022;56(5):228-3510.1007/s13139-022-00760-8.
6. Malone S, Wallis CJD, Lee-Ying R, Basappa NS, Cagiannos I, Hamilton RJ, Fernandes R, **Ferrario C**, Gotto GT, Morgan SC, Morash C, Niazi T, Noonan KL, Rendon R, Hotte SJ, Saad F, Zardan A, Osborne B, Chan KFY, Shayegan B. Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study. *BJUI Compass.* 2022;3(5):383-9110.1002/bco2.158.
7. Probst S, Bjartell A, Anand A, Skamene T, **Ferrario C**. Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. *Nucl Med Mol Imaging.* 2022;56(4):188-9510.1007/s13139-022-00754-6.
8. Shayegan B, Wallis CJD, Hamilton RJ, Morgan SC, Cagiannos I, Basappa NS, **Ferrario C**, Gotto GT, Fernandes R, Roy S, Noonan KL, Niazi T, Hotte SJ, Saad F, Hew H, Park-Wyllie L, Chan KFY, Malone S. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. *Prostate Cancer Prostatic Dis.* 202210.1038/s41391-022-00514-9.

Lorenzo Ferri

1. Alkaaki A, Abo Al-Saud A, Di Lena É, Ramirez-GarciaLuna JL, Najmeh S, Spicer J, **Ferri L**, Mulder D, Sirois C, Cools-Lartigue J. Factors predicting recurrence in thymic epithelial neoplasms. *Eur J Cardiothorac Surg.* 2022;62(5)10.1093/ejcts/ezac274.
2. Belia F, Biondi A, Agnes A, Santocchi P, Laurino A, Lorenzon L, Pezzuto R, Tirelli F, **Ferri L**, D'Ugo D, Persiani R. The Use of Indocyanine Green (ICG) and Near-Infrared (NIR) Fluorescence-Guided Imaging in Gastric Cancer Surgery: A Narrative Review. *Front Surg.* 2022;9:88077310.3389/fsurg.2022.880773.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

3. Bons J, Pan D, Shah S, Bai R, Chen-Tanyolac C, Wang X, Elliott DRF, Urisman A, O'Broin A, Basisty N, Rose J, Sangwan V, Camilleri-Broët S, Tankel J, Gascard P, **Ferri L**, Tlsty TD, Schilling B. Data-independent acquisition and quantification of extracellular matrix from human lung in chronic inflammation-associated carcinomas. *Proteomics*. 2022:e220002110.1002/pmic.202200021.
4. Chidambaram S, Patel NM, Sounderajah V, Alfieri R, Bonavina L, Cheong E, Cockbain A, D'Journo XB, **Ferri L**, Griffiths EA, Grimminger P, Gronnier C, Gutschow C, Hedberg J, Kauppila JH, Lagarde S, Low D, Naftoux P, Nieuwenhuijzen G, Nilsson M, Rosati R, Schroeder W, Smithers BM, van Berge Henegouwen MI, van Hillegesberg R, Watson DI, Vohra R, Maynard N, Markar SR. Identifying a core symptom set triggering radiological and endoscopic investigations for suspected recurrent esophago-gastric cancer: a modified Delphi consensus process. *Dis Esophagus*. 2022;36(1)10.1093/dote/doac038.
5. Cools-Lartigue J, Markar S, Mueller C, Hofstetter W, Nilsson M, Ilonen I, Soderstrom H, Rasanen J, Gisbertz S, Hanna GB, Elliott J, Reynolds J, Kisiel A, Griffiths E, Van Berge Henegouwen M, **Ferri L**. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. *Ann Surg*. 2022;276(5):799-80510.1097/sla.0000000000005619.
6. Donlon NE, Moran B, Kamilli A, Davern M, Sheppard A, King S, Donohoe CL, Lowery M, Cunningham M, Ravi N, Mueller C, Cools-Lartigue J, **Ferri L**, Reynolds JV. CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison. *Ann Surg*. 2022;276(5):792-810.1097/sla.0000000000005617.
7. Kamarajah SK, Siddaiah-Subramanya M, Parente A, Evans RPT, Adeyeye A, Ainsworth A, Takahashi AML, Charalabopoulos A, Chang A, Eroglue A, Wijnhoven B, Donohoe C, Molena D, Talavera-Urquijo E, Takeda FR, Darling G, Rosero G, Piessen G, Mahendran H, Kuei HP, Gockel I, Negoi I, Weindelmayer J, Rasanen J, Bekele K, Kim G, Depypere L, **Ferri L**, Nilsson M, Klevebro F, Smithers BM, van Berge Henegouwen MI, Grimminger P, Schneider PM, Pramesh CS, Sayyed R, Babor R, Mine S, Law S, Gisbertz S, Bright T, Benoit D'Journo X, Low D, Singh P, Griffiths EA. Risk Factors, Diagnosis and Management of Chyle Leak Following Esophagectomy for Cancers: An International Consensus Statement. *Ann Surg Open*. 2022;3(3):e19210.1097/as9.0000000000000192.
8. Nevo Y, Calderone A, Kammili A, Boulila C, Renaud S, Cools-Lartigue J, Spicer J, Mueller C, **Ferri L**. Endoscopic pyloromyotomy in minimally invasive esophagectomy: a novel approach. *Surg Endosc*. 2022;36(4):2341-810.1007/s00464-021-08511-0.
9. Nevo Y, Morency D, Kammili A, Abdrabo L, Zullo K, Almatar S, Cools-Lartigue J, **Ferri L**, Mueller C. The Role of Palliative Surgery in Stage IV Gastric Cancer: A Retrospective Study. *J Palliat Care*. 2022;37(2):152-810.1177/08258597221078382.
10. Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang QL, Johansson H, Gebiski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, **Ferri L**, Wong RK, O'Callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong FM, Chao YK, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. *Front Oncol.* 2022;12:91796110.3389/fonc.2022.917961.
11. Puri A, Patel NM, Sounderajah V, **Ferri L**, Griffiths EA, Low D, Maynard N, Mueller C, Pera M, van Berge Henegouwen MI, Watson DI, Zaninotto G, Hanna GB, Markar SR. Development of the ParaOesophageal hernia SympTom (POST) tool. *Br J Surg.* 2022;109(8):727-3210.1093/bjs/znac139.
 12. Sangwan V, Al-Marzouki L, Pal S, Stavrakos V, Alzahrani M, Antonatos D, Nevo Y, Camilleri-Broët S, Rayes R, Bourdeau F, Giannias B, Bertos N, Bailey S, Rousseau S, Cools-Lartigue J, Spicer JD, **Ferri L**. Inhibition of LPS-mediated TLR4 activation abrogates gastric adenocarcinoma-associated peritoneal metastasis. *Clin Exp Metastasis.* 2022;39(2):323-3310.1007/s10585-021-10133-8.
 13. Schmid S, Minnella EM, Pilon Y, Rokah M, Rayes R, Najmeh S, Cools-Lartigue J, **Ferri L**, Mulder D, Sirois C, Owen S, Shieh B, Ofiara L, Wong A, Sud S, Baldini G, Carli F, Spicer J. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care. *Clin Lung Cancer.* 2022;23(7):593-910.1016/j.clc.2022.05.004.
 14. Seitlinger J, Prieto M, Guerrero F, Streit A, Gauchotte G, Siat J, Falcoz PE, Massard G, **Ferri L**, Spicer J, Renaud S. Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes. *Clin Lung Cancer.* 2022;23(1):e29-e4210.1016/j.clc.2021.08.001.
 15. Shahzad MH, Feng L, Su X, Brassard A, Dhoparee-Doomah I, **Ferri LE**, Spicer JD, Cools-Lartigue JJ. Neutrophil Extracellular Traps in Cancer Therapy Resistance. *Cancers (Basel).* 2022;14(5)10.3390/cancers14051359.
 16. Sherwinter DA, Boni L, Bouvet M, **Ferri L**, Hyung WJ, Ishizawa T, Kaleya RN, Kelly K, Kokudo N, Lanzarini E, Luyer MDP, Mitsumori N, Mueller C, Park DJ, Ribero D, Rosati R, Ruurda JP, Sosef M, Schneider-Koraith S, Spinoglio G, Strong V, Takahashi N, Takeuchi H, Wijnhoven BPL, Yang HK, Dip F, Lo Menzo E, White KP, Rosenthal RJ. Use of fluorescence imaging and indocyanine green for sentinel node mapping during gastric cancer surgery: Results of an intercontinental Delphi survey. *Surgery.* 2022;172(6s):S29-s3710.1016/j.surg.2022.06.036.
 17. Tankel J, Calderone A, Garcia-Luna JLR, Mueller CL, Najmeh S, Spicer J, Mulder D, **Ferri L**, Cools-Lartigue J. Changes in Perioperative Platelet Lymphocyte Ratio Predict Survival in Oesophago-Gastric Adenocarcinoma. *Ann Surg Oncol.* 2022;10.1245/s10434-022-11475-7.
 18. Tankel J, Söderström H, Reizine E, Artho G, Calderone A, Mueller C, Najmeh S, Spicer J, **Ferri L**, Cools-Lartigue J. Change in Density Not Size of Esophageal Adenocarcinoma During Neoadjuvant Chemotherapy Is Associated with Improved Survival Outcomes. *J Gastrointest Surg.* 2022;26(12):2417-2510.1007/s11605-022-05422-w.
 19. Ubels S, Lubbers M, Verstegen MHP, Bouwense SAW, van Daele E, **Ferri L**, Gisbertz SS, Griffiths EA, Grimminger P, Hanna G, Hubka M, Law S, Low D, Luyer M, Merritt RE, Morse C, Mueller CL, Nieuwenhuijzen GAP, Nilsson M, Reynolds JV, Ribeiro U, Rosati R, Shen Y, Wijnhoven BPL, Klarenbeek BR, van Workum F, Rosman C. Treatment of anastomotic leak after esophagectomy: insights of an international case vignette survey and expert discussions. *Dis Esophagus.* 2022;35(12)10.1093/dote/doac020.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

20. Zhao H, Misariu AM, Ramirez-GarciaLuna JL, Nobel T, Mueller C, Cools-Lartigue J, Spicer J, Molena D, Bains M, Swisher S, Hofstetter W, **Ferri L**. Synchronous Esophageal and Lung Cancers-Is Combined Anatomic Resection Appropriate? *Ann Thorac Surg*. 2022;113(4):1354-6010.1016/j.athoracsur.2021.04.026.

William Foulkes

1. Alenezi WM, Fierheller CT, Revil T, Serruya C, Mes-Masson AM, **Foulkes WD**, Provencher D, El Haffaf Z, Ragoussis J, Tonin PN. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants. *Genes (Basel)*. 2022;13(4)10.3390/genes13040697.
2. Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, Behl S, Arcand SL, Nayar P, Spiegelman D, Gravel S, Mes-Masson AM, Provencher D, **Foulkes WD**, El Haffaf Z, Rouleau G, Bouchard L, Greenwood CMT, Masson JY, Ragoussis J, Tonin PN. The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. *Cancers (Basel)*. 2022;14(9)10.3390/cancers14092251.
3. Aronson M, Colas C, Shuen A, Hampel H, **Foulkes WD**, Baris Feldman H, Goldberg Y, Muleris M, Wolfe Schneider K, McGee RB, Jasperson K, Rangaswami A, Brugieres L, Tabori U. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. *J Med Genet*. 2022;59(4):318-2710.1136/jmedgenet-2020-107627.
4. Boni J, Idani A, Roca C, Feliubadaló L, Tomiak E, Weber E, **Foulkes WD**, Orthwein A, El Haffaf Z, Lazaro C, Rivera B. A decade of RAD51C and RAD51D germline variants in cancer. *Hum Mutat*. 2022;43(3):285-9810.1002/humu.24319.
5. Chen OJ, Castellsagué E, Moustafa-Kamal M, Nadaf J, Rivera B, Fahiminiya S, Wang Y, Gamache I, Pacifico C, Jiang L, Carrot-Zhang J, Witkowski L, Berghuis AM, Schönberger S, Schneider D, Hillmer M, Bens S, Siebert R, Stewart CJR, Zhang Z, Chao WCH, Greenwood CMT, Barford D, Tischkowitz M, Majewski J, **Foulkes WD**, Teodoro JG. Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer. *Cancer Res*. 2022;82(19):3499-51510.1158/0008-5472.Can-21-3956.
6. Chong AS, Apellaniz-Ruiz M, de Kock L, Bouron-Dal Soglio D, Doyle WR, Priest JR, Rivera B, **Foulkes WD**. Likely foregut endoderm origin for a postzygotic mutation affecting the RNase IIIb domain of DICER1. *J Med Genet*. 2022;59(7):723-610.1136/jmedgenet-2021-107887.
7. Clark KA, Paquette A, Tao K, Bell R, Boyle JL, Rosenthal J, Snow AK, Stark AW, Thompson BA, Unger J, Gertz J, Varley KE, Boucher KM, Goldgar DE, **Foulkes WD**, Thomas A, Tavtigian SV. Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. *Am J Hum Genet*. 2022;109(6):1153-7410.1016/j.ajhg.2022.05.004.
8. de Faria FW, Valera ET, Macedo C, Azevedo EF, Vieira AGS, Martins GE, da Cunha Júnior AG, Francisco Dos Reis MB, **Foulkes WD**, Lopes LF. Comment on: Consensus recommendations from the EXPeRT/PARTNER groups for the diagnosis and therapy of sex cord stromal tumors in children and adolescents. *Pediatr Blood Cancer*. 2022;69(9):e2965010.1002/pbc.29650.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

9. Finch A, Metcalfe K, Akbari M, Friedman E, Tung N, Rosen B, Eisen A, Karlan B, **Foulkes W**, Neuhausen SL, Senter L, McKinnon W, Elser C, Sun P, Narod SA. The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT. *Clin Genet.* 2022;101(3):317-2310.1111/cge.14098.
10. Gallon R, Phelps R, Hayes C, Brugieres L, Guerrini-Rousseau L, Colas C, Muleris M, Ryan NAJ, Evans DG, Grice H, Jessop E, Kunzemann-Martinez A, Marshall L, Schamschula E, Oberhuber K, Azizi AA, Baris Feldman H, Beilken A, Brauer N, Brozou T, Dahan K, Demirsoy U, Florkin B, **Foulkes W**, Januszkiewicz-Lewandowska D, Jones KJ, Kratz CP, Lobitz S, Meade J, Nathrath M, Pander HJ, Perne C, Ragab I, Ripperger T, Rosenbaum T, Rueda D, Sarosiek T, Sehested A, Spier I, Suerink M, Zimmermann SY, Zschocke J, Borthwick GM, Wimmer K, Burn J, Jackson MS, Santibanez-Koref M. Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency. *Gastroenterology.* 202210.1053/j.gastro.2022.12.017.
11. Gervais NJ, Gravelsins L, Brown A, Reuben R, Karkaby L, Baker-Sullivan E, Mendoza L, Lauzon C, Almey A, **Foulkes WD**, Bernardini MQ, Jacobson M, Velsher L, Rajah MN, Olsen RK, Grady C, Einstein G. Scene memory and hippocampal volume in middle-aged women with early hormone loss. *Neurobiol Aging.* 2022;117:97-10610.1016/j.neurobiolaging.2022.05.003.
12. Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, Domecq C, Bourdel G, Denroche RE, Jang GH, Grant RC, Borgida A, Grünwald BT, Dodd A, Wilson JM, Bourque G, O'Kane GM, Fischer SE, Kron CM, Fiset PO, Omeroglu A, **Foulkes WD**, Gallinger S, Guiot MC, Gao ZH, Zogopoulos G. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. *Front Oncol.* 2022;12:86076710.3389/fonc.2022.860767.
13. Kommos FK, Tessier-Cloutier B, Witkowski L, Forgo E, Koelsche C, Köbel M, **Foulkes WD**, Lee CH, Kolin DL, von Deimling A, Howitt BE. Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract. *J Pathol.* 2022;257(2):140-510.1002/path.5889.
14. Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, **Foulkes WD**, Neuhausen SL, Sun S, Karlan BY, Eisen A, Tung N, Olopade OI, Couch FJ, Huzarski T, Senter L, Bordeleau L, Singer CF, Eng C, Fruscio R, Pal T, Sun P, Narod SA. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. *Cancer Epidemiol Biomarkers Prev.* 2022;31(7):1351-810.1158/1055-9965.Epi-21-1196.
15. McCluggage WG, **Foulkes WD**. Rare and unusual tumours associated with characteristic molecular events: the importance of specialist pathology review. *Histopathology.* 2022;81(3):310-110.1111/his.14699.
16. McCluggage WG, Fu L, Mohler K, de Kock L, Sabbaghian N, Mindlin A, Stewart CJR, Gilks CB, **Foulkes WD**. An Unusual Enteric Yolk Sac Tumor: First Report of an Ovarian Germ Cell Tumor Associated With a Germline Pathogenic Variant in DICER1. *Int J Gynecol Pathol.* 2022;41(4):349-5510.1097/pgp.0000000000000818.
17. McCluggage WG, Rivera B, Chong AS, Clarke BA, Schultz KAP, Dehner LP, Tchraikian N, Apellaniz-Ruiz M, Gilks CB, Kommos F, Stewart CJR, **Foulkes WD**. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs. *Am J Surg Pathol.* 202210.1097/pas.0000000000002010.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

18. McCluggage WG, Stewart CJR, Belcijan NL, Mourad S, Goudie C, Chan JCK, Liu A, Alaggio R, **Foulkes WD**. Neuroectodermal elements are part of the morphological spectrum of DICER1-associated neoplasms. *Hum Pathol.* 2022;123:46-5810.1016/j.humpath.2022.02.018.
19. Mighton C, Smith AC, Mayers J, Tomaszewski R, Taylor S, Hume S, Agatep R, Spriggs E, Feilotter HE, Semenuk L, Wong H, Lazo de la Vega L, Marshall CR, Axford MM, Silver T, Charames GS, Di Gioacchino V, Watkins N, **Foulkes WD**, Clavier M, Hamel N, Chong G, Lamont RE, Parboosingh J, Karsan A, Bosdet I, Young SS, Tucker T, Akbari MR, Speevak MD, Vaags AK, Lebo MS, Lerner-Ellis J. Data sharing to improve concordance in variant interpretation across laboratories: results from the Canadian Open Genetics Repository. *J Med Genet.* 2022;59(6):571-810.1136/jmedgenet-2021-107738.
20. Niedziela M, Muchantef K, **Foulkes WD**. Ultrasound features of multinodular goiter in DICER1 syndrome. *Sci Rep.* 2022;12(1):1588810.1038/s41598-022-19709-0.
21. Nogué C, Chong AS, Grau E, Han H, Dorca E, Roca C, Mosquera JL, Lázaro C, **Foulkes WD**, Brunet J, Rivera B. DGCR8 and the six hit, three-step model of schwannomatosis. *Acta Neuropathol.* 2022;143(1):115-710.1007/s00401-021-02387-z.
22. Paixão D, Torrezan GT, Santiago KM, Formiga MN, Ahuno ST, Dias-Neto E, Tojal da Silva I, **Foulkes WD**, Polak P, Carraro DM. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients. *Front Oncol.* 2022;12:97695910.3389/fonc.2022.976959.
23. Pontén E, Frisk S, Taylan F, Vaz R, Wessman S, de Kock L, Pal N, **Foulkes WD**, Lagerstedt-Robinson K, Nordgren A. A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1. *J Med Genet.* 2022;59(2):141-610.1136/jmedgenet-2020-107385.
24. Sadinsky MB, Power J, Ambrosio E, Palma L, Zeng X, **Foulkes WD**, Weber E. Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer. *Curr Oncol.* 2022;29(5):3565-7510.3390/curroncol29050288.
25. Sherill-Rofe D, Raban O, Findlay S, Rahat D, Unterman I, Samiei A, Yasmeeen A, Kaiser Z, Kuasne H, Park M, **Foulkes WD**, Bloch I, Zick A, Gotlieb WH, Tabach Y, Orthwein A. Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. *NAR Cancer.* 2022;4(2):zcac01310.1093/narcan/zcac013.
26. Shickh S, Oldfield LE, Clausen M, Mighton C, Sebastian A, Calvo A, Baxter NN, Dawson L, Penney LS, **Foulkes W**, Basik M, Sun S, Schrader KA, Regier DA, Karsan A, Pollett A, Pugh TJ, Kim RH, Bombard Y. "Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. *Oncologist.* 2022;27(5):e393-e40110.1093/oncolo/oyac039.
27. Štancl P, Hamel N, Sigel KM, **Foulkes WD**, Karlić R, Polak P. The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes. *Front Genet.* 2022;13:85215910.3389/fgene.2022.852159.
28. Sui L, Wang S, Ganguly D, El Rayes TP, Askeland C, Børretzen A, Sim D, Halvorsen OJ, Knutsvik G, Arnes J, Aziz S, Haukaas S, **Foulkes WD**, Bielenberg DR, Ziemys A, Mittal V, Brekken RA, Akslen LA, Watnick RS. PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. *Nat Commun.* 2022;13(1):795910.1038/s41467-022-35649-9.
29. Tchrakian N, Oliva E, Chong AS, Rivera-Polo B, Bennett JA, Nucci MR, Sah S, Schoolmeester JK, van der Griend RA, **Foulkes WD**, Clarke BA, Young RH, McCluggage

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- WG. Ovarian Signet-ring Stromal Tumor: A Morphologic, Immunohistochemical, and Molecular Study of 7 Cases With Discussion of the Differential Diagnosis. *Am J Surg Pathol.* 2022;46(12):1599-61010.1097/pas.0000000000001954.
30. Tessier-Cloutier B, Kleinman CL, **Foulkes WD**. SWI/SNF-deficient undifferentiated malignancies: where to draw the line(†). *J Pathol.* 2022;256(2):139-4210.1002/path.5836.
31. Thorner PS, Chong AS, Nadaf J, Benlimame N, Marrano P, Chami R, Fu L, **Foulkes WD**. PRAME protein expression in DICER1-related tumours. *J Pathol Clin Res.* 2022;8(6):579-8110.1002/cjp2.293.
32. Thorner PS, Chong AS, Nadaf J, Benlimame N, Marrano P, Chami R, Fu L, **Foulkes WD**. PRAME protein expression in DICER1-related tumours. *J Pathol Clin Res.* 2022;8(3):294-30410.1002/cjp2.264.
33. Tindale LC, Zhantuyakova A, Lam S, Woo M, Kwon JS, Hanley GE, Knoppers B, Schrader KA, Peacock SJ, Talhouk A, Dummer T, Metcalfe K, Pashayan N, **Foulkes WD**, Manchanda R, Huntsman D, Stuart G, Simard J, Dawson L. Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention. *Curr Oncol.* 2022;29(7):4632-4610.3390/curroncol29070368.
34. Wang Y, Cuggia A, Chen YI, Parent J, Stanek A, Denroche RE, Zhang A, Grant RC, Domecq C, Golesworthy B, Shwaartz C, Borgida A, Holter S, Wilson JM, Chong G, O'Kane GM, Knox JJ, Fischer SE, Gallinger S, Gao ZH, **Foulkes WD**, Waschke KA, Zogopoulos G. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? *J Natl Compr Canc Netw.* 2022;20(6):663-73.e1210.6004/jnccn.2021.7107.
35. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, **Foulkes WD**, Zogopoulos G. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet.* 2022;59(8):793-80010.1136/jmedgenet-2021-108054.
36. Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, **Foulkes WD**. ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol.* 2022;29(11):6671-210.1245/s10434-022-12011-3.
37. Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, **Foulkes WD**. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol.* 2022;29(11):6660-810.1245/s10434-022-11916-3.
38. Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, **Foulkes WD**, Sun P, Narod SA, Kotsopoulos J. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. *Gynecol Oncol.* 2022;164(3):514-2110.1016/j.ygyno.2022.01.014.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Eduardo Franco

1. Andrade Pessoa Morales J, Marconi C, El-Zein M, Ravel J, da Silva Pinto GV, Silveira R, Lima MD, de Carvalho NS, Alves RRF, de Lima Parada CMG, Leite SHM, Villa LL, **Franco EL**, da Silva MG. Vaginal Microbiome Components as Correlates of Cervical Human Papillomavirus Infection. *J Infect Dis.* 2022;226(6):1084-9710.1093/infdis/jiab547.
2. Arthur AW, Shinder GA, Logel M, Mullen CJ, Tope P, **Franco EL**. Preventive Medicine: Topical diversity and rigour 50 years on. *Prev Med.* 2022;164:10733710.1016/j.ypmed.2022.107337.
3. Coutlée F, de Pokomandy A, Burchell AN, El-Zein M, Mayrand MH, Rodrigues-Coutlée S, Money D, Comète É, McClymont E, Rouleau D, **Franco EL**. Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples. *J Med Virol.* 2022;94(6):2824-3210.1002/jmv.27605.
4. **Franco EL**, El-Zein M. Reply. *J Infect Dis.* 2022;225(5):924-510.1093/infdis/jiab471.
5. Gapare CR, El-Zein M, Patel H, Tope P, **Franco EL**. Ecologic Analysis of Correlates of Cervical Cancer Morbidity and Mortality in Sub-Saharan Africa. *Cancer Epidemiol Biomarkers Prev.* 2022;31(9):1804-1110.1158/1055-9965.Epi-22-0193.
6. Gottschlich A, Gondara L, Smith LW, Cook D, Martin RE, Lee M, Peacock S, Proctor L, Stuart G, Krajden M, **Franco EL**, van Niekerk D, Ogilvie G. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial. *Int J Cancer.* 2022;151(6):897-90510.1002/ijc.34039.
7. Hurtado-Salgado E, Cárdenas-Cárdenas L, Salmerón J, Luna-Gordillo R, Ortiz-Panozo E, Allen-Leigh B, Saavedra-Lara N, **Franco EL**, Lazcano-Ponce E. Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level. *Int J Cancer.* 2022;150(9):1422-3010.1002/ijc.33905.
8. Laurie C, El-Zein M, Tota JE, Khosrow-Khavar F, Tellier PP, Coutlée F, de Pokomandy A, **Franco EL**. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. *Sex Transm Infect.* 2022;98(4):239-4610.1136/sextrans-2021-055009.
9. Lesack A, Smith LW, Racey CS, Gondara L, Krajden M, Lee M, Martin RE, Stuart G, Peacock S, **Franco EL**, van Niekerk D, Ogilvie GS. Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results. *Curr Oncol.* 2022;29(6):3860-910.3390/currenocol29060308.
10. Logel M, Laurie C, El-Zein M, Guichon J, **Franco EL**. A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination. *Cancer Epidemiol Biomarkers Prev.* 2022;31(5):919-3110.1158/1055-9965.Epi-21-1256.
11. Logel M, Tope P, Arthur A, Mullen CJR, Shinder GA, **Franco EL**. A Golden Jubilee Editorial - Preventive Medicine's contributions to the science of cervical cancer elimination. *Prev Med.* 2022;164:10731710.1016/j.ypmed.2022.107317.
12. Louvanto K, Baral P, Burchell A, Ramanakumar A, El-Zein M, Tellier PP, Coutlée F, Roger M, **Franco EL**. Role of Human Leukocyte Antigen Allele Sharing in Human Papillomavirus Infection Transmission Among Heterosexual Couples: Findings From the HITCH Cohort Study. *J Infect Dis.* 2022;226(7):1175-8310.1093/infdis/jiac115.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

13. MacCosham A, El-Zein M, Burchell AN, Tellier PP, Coutlée F, **Franco EL**. Protection to Self and to One's Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study. *Sex Transm Dis*. 2022;49(6):414-2210.1097/olq.0000000000001620.
14. Malagón T, MacCosham A, Burchell AN, El-Zein M, Tellier PP, Coutlée F, **Franco EL**. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. *Clin Infect Dis*. 2022;75(3):365-7110.1093/cid/ciab985.
15. Malagón T, Yong JHE, Tope P, Miller WH, Jr., **Franco EL**. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada. *Int J Cancer*. 2022;150(8):1244-5410.1002/ijc.33884.
16. Morais S, Wissing MD, Khosrow-Khavar F, Burchell AN, Tellier PP, Coutlée F, Waterboer T, El-Zein M, **Franco EL**. Serologic response to human papillomavirus genotypes among unvaccinated females: Findings from the HITCH cohort study. *J Infect Dis*. 202210.1093/infdis/jiac437.
17. Shapiro SB, Wissing MD, Khosrow-Khavar F, El-Zein M, Burchell AN, Tellier PP, Coutlée F, **Franco EL**. Male Circumcision and Genital Human Papillomavirus (HPV) Infection in Males and Their Female Sexual Partners: Findings From the HPV Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study. *J Infect Dis*. 2022;226(7):1184-9410.1093/infdis/jiac147.
18. Shinder GA, Arthur A, Logel M, Mullen CJR, Tope P, **Franco EL**. Overview of Preventive Medicine's thematic article collections- A golden jubilee editorial. *Prev Med*. 2022;162:10717810.1016/j.ypmed.2022.107178.
19. Tejada RA, Malagón T, **Franco EL**. Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis. *Vaccine*. 2022;40(19):2667-7810.1016/j.vaccine.2022.03.046.
20. Tope P, Shinder GA, Arthur A, Logel M, Mullen CJ, **Franco EL**. Revisiting a neglected public health priority: Research on gun violence prevention. *Prev Med*. 2022;165(Pt A):10730010.1016/j.ypmed.2022.107300.
21. Volesky KD, Magnan S, Mayrand MH, Isidean SD, El-Zein M, Comète E, **Franco EL**, Coutlée F. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening. *Cancer Epidemiol Biomarkers Prev*. 2022;31(4):851-710.1158/1055-9965.Epi-21-1082.

Carolyn Freeman

1. Safavi AH, **Freeman C**, Cheng S, Patel S, Mitera G, Kundapur V, Rutledge R, Tsang DS. Proton Therapy in Canada: Toward Universal Access and Health Equity With a Publicly Funded Facility. *Int J Radiat Oncol Biol Phys*. 202210.1016/j.ijrobp.2022.12.021.

Jennifer Friedmann

1. Kasymjanova G, Rizzolo A, Pepe C, **Friedmann JE**, Small D, Spicer J, Lecavalier-Barsoum M, Sultanem K, Wang H, Spatz A, Cohen V, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol*. 2022;29(11):8677-8510.3390/currenocol29110684.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Vincent Giguère

1. Bramhecha YM, Guérard KP, Audet-Walsh É, Rouzbeh S, Kassem O, Pernet E, Scarlata E, Hamel L, Brimo F, Divangahi M, Aprikian AG, Chevalier S, **Giguère V**, Lapointe J. Fatty acid oxidation enzyme $\Delta 3$, $\Delta 2$ -enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. *Oncogene*. 2022;41(20):2798-81010.1038/s41388-022-02276-z.
2. Dufour CR, Scholtes C, Yan M, Chen Y, Han L, Li T, Xia H, Deng Q, Vernier M, **Giguère V**. The mTOR chromatin-bound interactome in prostate cancer. *Cell Rep*. 2022;38(12):11053410.1016/j.celrep.2022.110534.
3. Dufour CR, Xia H, B'Chir W, Perry MC, Kuzmanov U, Gainullina A, Dejgaard K, Scholtes C, Ouellet C, Zuo D, Sanguin-Gendreau V, Guluzian C, Smith HW, Muller WJ, Audet-Walsh E, Sergushichev AA, Emili A, **Giguère V**. Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and $ERR\alpha$ deficiency. *Commun Biol*. 2022;5(1):95510.1038/s42003-022-03942-4.
4. Farooq Z, Kusuma F, Burke P, Dufour CR, Lee D, Tabatabaei N, Toboz P, Radovani E, Greenblatt JF, Rehman J, Class J, Khoutorsky A, Fonseca BD, Richner JM, Mercier E, Bourque G, **Giguère V**, Subramaniam AR, Han J, Tahmasebi S. The amino acid sensor GCN2 suppresses terminal oligopyrimidine (TOP) mRNA translation via La-related protein 1 (LARP1). *J Biol Chem*. 2022;298(9):10227710.1016/j.jbc.2022.102277.
5. **Giguère V**. Retinoic acid receptors at 35: molecular convergence of vitamin A and steroid hormone action. *J Mol Endocrinol*. 2022;69(4):E1-e310.1530/jme-22-0155.
6. **Giguère V**, Evans RM. Chronicle of a discovery: the retinoic acid receptor. *J Mol Endocrinol*. 2022;69(4):T1-t1110.1530/jme-22-0117.
7. Rahbani JF, Scholtes C, Lagarde DM, Hussain MF, Roesler A, Dykstra CB, Bunk J, Samborska B, O'Brien SL, Tripp E, Pacis A, Angueira AR, Johansen OS, Cinkornpumin J, Hossain I, Lynes MD, Zhang Y, White AP, Pastor WA, Chondronikola M, Sidossis L, Klein S, Kralli A, Cypess AM, Pedersen SB, Jessen N, Tseng YH, Gerhart-Hines Z, Seale P, Calebiro D, **Giguère V**, Kazak L. ADRA1A-G α (q) signalling potentiates adipocyte thermogenesis through CKB and TNAP. *Nat Metab*. 2022;4(11):1459-7310.1038/s42255-022-00667-w.
8. Scholtes C, Dufour CR, **Giguère V**. Rapid immunoprecipitation mass spectrometry of endogenous protein (RIME) to identify chromatin-interactome in prostate cancer cells. *STAR Protoc*. 2022;3(2):10143410.1016/j.xpro.2022.101434.
9. Scholtes C, **Giguère V**. Transcriptional control of energy metabolism by nuclear receptors. *Nat Rev Mol Cell Biol*. 2022;23(11):750-7010.1038/s41580-022-00486-7.
10. Toboz P, Amiri M, Tabatabaei N, Dufour CR, Kim SH, Fillebeen C, Ayemoba CE, Khoutorsky A, Nairz M, Shao L, Pajcini KV, Kim KW, **Giguère V**, Oliveira RL, Constante M, Santos MM, Morales CR, Pantopoulos K, Sonenberg N, Pinho S, Tahmasebi S. The amino acid sensor GCN2 controls red blood cell clearance and iron metabolism through regulation of liver macrophages. *Proc Natl Acad Sci U S A*. 2022;119(35):e21212511910.1073/pnas.2121251119.
11. Xia H, Scholtes C, Dufour CR, Ouellet C, Ghahremani M, **Giguère V**. Insulin action and resistance are dependent on a GSK3 β -FBXW7- $ERR\alpha$ transcriptional axis. *Nat Commun*. 2022;13(1):210510.1038/s41467-022-29722-6.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Lucy Gilbert

1. Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, **Gilbert L**, Black D, Kabil N, Bennett J, Munley J, Aghajanian C. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. *Gynecol Oncol.* 2022;166(3):425-3110.1016/j.ygyno.2022.06.017.
2. F AL, De Las Vecillas Sanchez L, **Gilbert L**, Copaescu AM, Isabwe GAC. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review. *Clin Rev Allergy Immunol.* 2022;62(3):534-4710.1007/s12016-022-08932-2.
3. Grundy A, Sandhu S, Arseneau J, **Gilbert L**, Gotlieb WH, Aronson KJ, Koushik A. Lifetime caffeine intake and the risk of epithelial ovarian cancer. *Cancer Epidemiol.* 2022;76:10205810.1016/j.canep.2021.102058.
4. Marth C, Tarnawski R, Tyulyandina A, Pignata S, **Gilbert L**, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. *Int J Gynecol Cancer.* 2022;32(1):93-10010.1136/ijgc-2021-003017.
5. Oaknin A, **Gilbert L**, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C, III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer.* 2022;10(1)10.1136/jitc-2021-003777.

Walter Gotlieb

1. Abitbol J, Kucukyazici B, Brin S, Lau S, Salvador S, Ramanakumar AV, Kessous R, Kogan L, Fletcher JD, Pare-Miron V, Liu G, **Gotlieb WH**. Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer. *J Robot Surg.* 202210.1007/s11701-022-01447-0.
2. Ahmed S, **Gotlieb WH**, Erez G, Loisel CG. Perceptions of BELONG as a supportive e-platform used by women with gynecologic cancers. *Psychooncology.* 2022;31(1):152-610.1002/pon.5785.
3. Cyr MP, Dostie R, Camden C, Dumoulin C, Bessette P, Pina A, **Gotlieb WH**, Lapointe-Milot K, Mayrand MH, Morin M. Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: Results from a one-year follow-up mixed-method study. *PLoS One.* 2022;17(1):e026284410.1371/journal.pone.0262844.
4. Cyr MP, Dostie R, Camden C, Dumoulin C, Bessette P, Pina A, **Gotlieb WH**, Lapointe-Milot K, Mayrand MH, Morin M. Acceptability of multimodal pelvic floor physical therapy to treat dyspareunia after gynecological malignancies: a qualitative study of women's views and experiences. *Int Urogynecol J.* 2022;1-1310.1007/s00192-022-05304-4.
5. Cyr MP, Dumoulin C, Bessette P, Pina A, **Gotlieb WH**, Lapointe-Milot K, Mayrand MH, Morin M. Changes in pelvic floor morphometry and muscle function after multimodal physiotherapy for gynaecological cancer survivors suffering from dyspareunia: a

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- prospective interventional study. *Physiotherapy*. 2022;114:54-6210.1016/j.physio.2021.09.003.
6. Gomolin A, **Gotlieb W**, Lau S, Salvador S, Racovitan F, Abitbol J. Mandate to evaluate robotic surgery implementation: a 12-year retrospective analysis of impact and future implications. *J Robot Surg*. 2022;16(4):783-810.1007/s11701-021-01327-z.
 7. Grundy A, Sandhu S, Arseneau J, Gilbert L, **Gotlieb WH**, Aronson KJ, Koushik A. Lifetime caffeine intake and the risk of epithelial ovarian cancer. *Cancer Epidemiol*. 2022;76:10205810.1016/j.canep.2021.102058.
 8. Jamieson A, Huvila J, Thompson EF, Leung S, Chiu D, Lum A, McConechy M, Grondin K, Aguirre-Hernandez R, Salvador S, Kean S, Samouelian V, Gougeon F, Azordegan N, Lytwyn A, Parra-Herran C, Offman S, **Gotlieb W**, Irving J, Kinloch M, Helpman L, Scott SA, Vicus D, Plante M, Huntsman DG, Gilks CB, Talhouk A, McAlpine JN. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. *Gynecol Oncol*. 2022;165(2):201-1410.1016/j.ygyno.2022.02.001.
 9. Matanes E, Amajoud Z, Salvador S, Lau S, **Gotlieb W**. Four protective maneuvers in minimal invasive surgery of endometrial cancer. *Int J Gynecol Cancer*. 2022;32(7):953-410.1136/ijgc-2021-003324.
 10. Matanes E, Cantor T, AlShehri E, Salvador S, Lau S, **Gotlieb W**. Surgical technique for sentinel lymph node sampling in endometrial cancer using the articulated HOOK monopolar instrument. *Int J Gynecol Cancer*. 2022;32(7):951-210.1136/ijgc-2021-002840.
 11. Matanes E, Eisenberg N, Mitric C, Yasmeen A, Ismail S, Raban O, Cantor T, Knigin D, Lau S, Salvador S, **Gotlieb W**, Kogan L. Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma. *Int J Gynecol Cancer*. 2022;32(7):875-8110.1136/ijgc-2022-003431.
 12. Piedimonte S, Feigenberg T, Drysdale E, Kwon J, **Gotlieb WH**, Cormier B, Plante M, Lau S, Helpman L, Renaud MC, May T, Vicus D. Predicting recurrence and recurrence-free survival in high-grade endometrial cancer using machine learning. *J Surg Oncol*. 2022;126(6):1096-10310.1002/jso.27008.
 13. Schnitman G, Wang T, Kundu S, Turkdogan S, Gotlieb R, How J, **Gotlieb W**. The role of digital patient education in maternal health: A systematic review. *Patient Educ Couns*. 2022;105(3):586-9310.1016/j.pec.2021.06.019.
 14. Sherill-Rofe D, Raban O, Findlay S, Rahat D, Unterman I, Samiei A, Yasmeen A, Kaiser Z, Kuasne H, Park M, Foulkes WD, Bloch I, Zick A, **Gotlieb WH**, Tabach Y, Orthwein A. Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. *NAR Cancer*. 2022;4(2):zcac01310.1093/narcan/zcac013.
 15. Thompson EF, Huvila J, Jamieson A, Leung S, Lum A, Offman S, Lytwyn A, Sur ML, Hoang L, Irving J, van der Westhuizen N, Morin C, Bicomumpaka C, Azordegan N, Gougeon F, Ennour-Idrissi K, Senz J, McConechy MK, Aguirre-Hernandez R, Lui V, Kuo C, Bell C, Salisbury T, Lawson J, He E, Wang S, Chiu D, Kean S, Samouelian V, Salvador S, **Gotlieb W**, Helpman L, Scott S, Wohlmuth C, Vicus D, Plante M, Talhouk A, Huntsman D, Parra-Herran C, Kinloch M, Grondin K, Gilks CB, McAlpine JN. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification. *Mod Pathol*. 2022;35(12):1974-8210.1038/s41379-022-01165-w.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Celia Greenwood

1. Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, Behl S, Arcand SL, Nayar P, Spiegelman D, Gravel S, Mes-Masson AM, Provencher D, Foulkes WD, El Haffaf Z, Rouleau G, Bouchard L, **Greenwood CMT**, Masson JY, Ragoussis J, Tonin PN. The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. *Cancers (Basel)*. 2022;14(9):10.3390/cancers14092251.
2. Butler-Laporte G, Gonzalez-Kozlova E, Su CY, Zhou S, Nakanishi T, Brunet-Ratnasingham E, Morrison D, Laurent L, Afilalo J, Afilalo M, Henry D, Chen Y, Carrasco-Zanini J, Farjoun Y, Pietzner M, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Moussa Y, DeLuca C, Duggan N, Schurr E, Brassard N, Durand M, Del Valle DM, Thompson R, Cedillo MA, Schadt E, Nie K, Simons NW, Mouskas K, Zaki N, Patel M, Xie H, Harris J, Marvin R, Cheng E, Tuballes K, Argueta K, Scott I, **Greenwood CMT**, Paterson C, Hinterberg M, Langenberg C, Forgetta V, Mooser V, Marron T, Beckmann N, Kenigsberg E, Charney AW, Kim-Schulze S, Merad M, Kaufmann DE, Gnjatic S, Richards JB. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. *Clin Proteomics*. 2022;19(1):3410.1186/s12014-022-09371-z.
3. Butler-Laporte G, Gonzalez-Kozlova E, Su CY, Zhou S, Nakanishi T, Brunet-Ratnasingham E, Morrison D, Laurent L, Aflalo J, Aflalo M, Henry D, Chen Y, Carrasco-Zanini J, Farjoun Y, Pietzner M, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Moussa Y, DeLuca C, Duggan N, Schurr E, Brassard N, Durand M, Del Valle DM, Thompson R, Cedillo MA, Schadt E, Nie K, Simons NW, Mouskas K, Zaki N, Patel M, Xie H, Harris J, Marvin R, Cheng E, Tuballes K, Argueta K, Scott I, **Greenwood CMT**, Paterson C, Hinterberg M, Langenberg C, Forgetta V, Mooser V, Marron T, Beckmann ND, Kenigsberg E, Charney AW, Kim-Schulze S, Merad M, Kaufmann DE, Gnjatic S, Richards JB. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. *Clin Proteomics*. 2022;19(1):4010.1186/s12014-022-09378-6.
4. Chen OJ, Castellsagué E, Moustafa-Kamal M, Nadaf J, Rivera B, Fahiminiya S, Wang Y, Gamache I, Pacifico C, Jiang L, Carrot-Zhang J, Witkowski L, Berghuis AM, Schönberger S, Schneider D, Hillmer M, Bens S, Siebert R, Stewart CJR, Zhang Z, Chao WCH, **Greenwood CMT**, Barford D, Tischkowitz M, Majewski J, Foulkes WD, Teodoro JG. Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer. *Cancer Res*. 2022;82(19):3499-51510.1158/0008-5472.Can-21-3956.
5. Ferdous T, Jiang L, Dinu I, Groizeleau J, Kozyrskyj AL, **Greenwood CMT**, Arrieta MC. The rise to power of the microbiome: power and sample size calculation for microbiome studies. *Mucosal Immunol*. 2022;15(6):1060-7010.1038/s41385-022-00548-1.
6. Forgetta V, Jiang L, Vulpescu NA, Hogan MS, Chen S, Morris JA, Grinek S, Benner C, Jang DK, Hoang Q, Burt N, Flannick JA, McCarthy MI, Fauman E, **Greenwood CMT**, Maurano MT, Richards JB. An effector index to predict target genes at GWAS loci. *Hum Genet*. 2022;141(8):1431-4710.1007/s00439-022-02434-z.
7. Jiang L, Greenlaw K, Ciampi A, Canty AJ, Gross J, Turecki G, **Greenwood CMT**. A Bayesian hierarchical model for improving measurement of 5mC and 5hmC levels: Toward

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- revealing associations between phenotypes and methylation states. *Genet Epidemiol.* 2022;46(7):446-6210.1002/gepi.22489.
8. Lebeau B, Zhao K, Jangal M, Zhao T, Guerra M, **Greenwood CMT**, Witcher M. Single base-pair resolution analysis of DNA binding motif with MoMotif reveals an oncogenic function of CTCF zinc-finger 1 mutation. *Nucleic Acids Res.* 2022;50(15):8441-5810.1093/nar/gkac658.
 9. Lu T, Forgetta V, **Greenwood CMT**, Richards JB. Identifying Causes of Fracture Beyond Bone Mineral Density: Evidence From Human Genetics. *J Bone Miner Res.* 2022;37(8):1592-60210.1002/jbmr.4632.
 10. Lu T, Forgetta V, Richards JB, **Greenwood CMT**. Genetic determinants of polygenic prediction accuracy within a population. *Genetics.* 2022;222(4)10.1093/genetics/iyac158.
 11. Lu T, Forgetta V, Richards JB, **Greenwood CMT**. Capturing additional genetic risk from family history for improved polygenic risk prediction. *Commun Biol.* 2022;5(1):59510.1038/s42003-022-03532-4.
 12. Lu T, Forgetta V, Richards JB, **Greenwood CMT**. Polygenic risk score as a possible tool for identifying familial monogenic causes of complex diseases. *Genet Med.* 2022;24(7):1545-5510.1016/j.gim.2022.03.022.
 13. Neumann A, Jolicoeur-Martineau A, Szekely E, Sallis HM, O'Donnel K, **Greenwood CMT**, Levitan R, Meaney MJ, Wazana A, Evans J, Tiemeier H. Combined polygenic risk scores of different psychiatric traits predict general and specific psychopathology in childhood. *J Child Psychol Psychiatry.* 2022;63(6):636-4510.1111/jcpp.13501.
 14. Shao X, Vishweswaraiyah S, Čuperlović-Culf M, Yilmaz A, **Greenwood CMT**, Surendra A, McGuinness B, Passmore P, Kehoe PG, Maddens ME, Bennett SAL, Green BD, Radhakrishna U, Graham SF. Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential. *Commun Biol.* 2022;5(1):127910.1038/s42003-022-03965-x.
 15. St-Pierre J, Zhang X, Lu T, Jiang L, Loffree X, Wang L, Bhatnagar S, **Greenwood CMT**. Considering strategies for SNP selection in genetic and polygenic risk scores. *Front Genet.* 2022;13:90059510.3389/fgene.2022.900595.

Gyorgy Hegyi

1. Deyirmendjian C, Lee S, Noureldin YA, **Hegyi G**, Stein L, Artho G, Andonian S. Not Every Low-Dose Is Low-Dose: Impact of Revising Low-Dose CT Protocol on Mean Effective Radiation Exposure. *J Endourol.* 2022;36(6):835-4010.1089/end.2021.0659.

Melissa Henry

1. Albert JG, Lo C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Sultanem K, Shenouda G, Cury FL, **Henry M**. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol.* 2022;29(7):4438-5410.3390/currenol29070353.
2. Cherba M, Brumans B, Hier MP, Giguère L, Chartier G, Jacobs H, Forest VI, Mlynarek A, Sultanem K, **Henry M**. Framing Concerns about Body Image during Pre- and Post-Surgical Consultations for Head and Neck Cancer: A Qualitative Study of Patient-Physician Interactions. *Curr Oncol.* 2022;29(5):3341-6310.3390/currenol29050272.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

3. **Henry M**, Albert JG, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Lo C, Rosberger Z. Body Image Concerns in Patients With Head and Neck Cancer: A Longitudinal Study. *Front Psychol.* 2022;13:81658710.3389/fpsyg.2022.816587.
4. **Henry M**, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Rosberger Z. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology.* 2022;31(2):185-9710.1002/pon.5803.
5. Landry V, Siciliani E, **Henry M**, Payne RJ. Health-Related Quality of Life following Total Thyroidectomy and Lobectomy for Differentiated Thyroid Carcinoma: A Systematic Review. *Curr Oncol.* 2022;29(7):4386-42210.3390/curroncol29070350.
6. Mascarella MA, Morand GB, Hier MP, Mlynarek A, Albert JG, Kissane D, **Henry M**. Dealing with the Vicissitudes and Abject Consequences of Head and Neck Cancer: A Vital Role for Psycho-Oncology. *Curr Oncol.* 2022;29(9):6714-2310.3390/curroncol29090527.
7. Silver JA, Turkdogan S, Roy CF, Subramaniam T, **Henry M**, Sadeghi N. De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma-Where Are We Now? *Curr Oncol.* 2022;29(5):3668-9710.3390/curroncol29050295.

Michael Hier

1. Albert JG, Lo C, Rosberger Z, Frenkiel S, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Sultanem K, Shenouda G, Cury FL, Henry M. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol.* 2022;29(7):4438-5410.3390/curroncol29070353.
2. Castellano LRC, Cruz S, **Hier M**, Bonan PRF, Alaoui-Jamali MA, da Silva SD. Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma. *Cancers (Basel).* 2022;14(21)10.3390/cancers14215406.
3. Cherba M, Brummans B, **Hier MP**, Giguère L, Chartier G, Jacobs H, Forest VI, Mlynarek A, Sultanem K, Henry M. Framing Concerns about Body Image during Pre- and Post-Surgical Consultations for Head and Neck Cancer: A Qualitative Study of Patient-Physician Interactions. *Curr Oncol.* 2022;29(5):3341-6310.3390/curroncol29050272.
4. da Silva SD, Morand GB, Diesel L, de Lima JM, Bijian K, Kailasam S, Lefebvre F, Bourque G, **Hier M**, Alaoui-Jamali MA. Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV(600E)-Positive Papillary Thyroid Cancer. *Cells.* 2022;12(1)10.3390/cells12010139.
5. Elsherbini N, Kim DH, Payne RJ, Hudson T, Forest VI, **Hier MP**, Payne AE, Pusztaszeri MP. EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles. *J Otolaryngol Head Neck Surg.* 2022;51(1):4310.1186/s40463-022-00594-6.
6. Henry M, Albert JG, Frenkiel S, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Lo C, Rosberger Z. Body Image Concerns in Patients With Head and Neck Cancer: A Longitudinal Study. *Front Psychol.* 2022;13:81658710.3389/fpsyg.2022.816587.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

7. Henry M, Arnovitz E, Frenkiel S, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Rosberger Z. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology*. 2022;31(2):185-9710.1002/pon.5803.
8. Hutchinson KA, Guerra A, Payne AE, Turkdogan S, Forest VI, **Hier MP**, Payne RJ. Risk Factors Associated With Reoperative Surgery for Thyroid Malignancies: A Retrospective Cohort Study. *Otolaryngol Head Neck Surg*. 2022:194599822109979910.1177/01945998221099799.
9. Mascarella MA, Morand GB, **Hier MP**, Mlynarek A, Albert JG, Kissane D, Henry M. Dealing with the Vicissitudes and Abject Consequences of Head and Neck Cancer: A Vital Role for Psycho-Oncology. *Curr Oncol*. 2022;29(9):6714-2310.3390/curroncol29090527.
10. Mascarella MA, Muthukrishnan N, Maleki F, Kergoat MJ, Richardson K, Mlynarek A, Forest VI, Reinhold C, Martin DR, **Hier M**, Sadeghi N, Forghani R. Above and Beyond Age: Prediction of Major Postoperative Adverse Events in Head and Neck Surgery. *Ann Otol Rhinol Laryngol*. 2022;131(7):697-70310.1177/00034894211041222.
11. Mascarella MA, Peeva M, Forest VI, Pusztaszeri MP, Avior G, Tamilia M, Mlynarek AM, **Hier MP**, Payne RJ. Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy. *Clin Otolaryngol*. 2022;47(1):75-8010.1111/coa.13859.
12. Mohtashami S, Richardson K, Forest VI, Mlynarek A, Payne RJ, Tamilia M, Pusztaszeri MP, **Hier MP**, Sadeghi N, Mascarella MA. Thyroidectomy for Graves' Disease Predicts Postoperative Neck Hematoma and Hypocalcemia: A North American cohort study. *Ann Otol Rhinol Laryngol*. 2022;131(4):341-5110.1177/00034894211021288.
13. Morand GB, Alsayegh R, Mlynarek AM, Plourde M, Mach T, Mascarella MA, **Hier MP**, Florianova L, Pusztaszeri MP. Application of the Milan system for reporting salivary gland cytopathology using cell blocks. *Virchows Arch*. 2022;481(4):575-8310.1007/s00428-022-03364-x.
14. Morand GB, Cardona I, Cruz S, Mlynarek AM, **Hier MP**, Alaoui-Jamali MA, da Silva SD. Therapeutic Vaccines for HPV-Associated Oropharyngeal and Cervical Cancer: The Next De-Intensification Strategy? *Int J Mol Sci*. 2022;23(15)10.3390/ijms23158395.
15. Morand GB, Diaconescu A, Ibrahim I, Lamarche G, Ruas JS, Dalfen J, **Hier MP**, Alaoui-Jamali MA, Maschietto M, da Silva SD. Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review. *Clin Exp Metastasis*. 2022;39(3):407-1610.1007/s10585-022-10148-9.
16. Morand GB, Sultanem K, Mascarella MA, **Hier MP**, Mlynarek AM. Historical Perspective: How the Discovery of HPV Virus Led to the Utilization of a Robot. *Front Oral Health*. 2022;3:91286110.3389/froh.2022.912861.
17. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, **Hier M**, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Odell M, Parker C, Wehrli B, Kwan K, Palma DA. Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial. *J Clin Oncol*. 2022;40(8):866-7510.1200/jco.21.01961.
18. Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, **Hier M**, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

- J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2022;8(6):1-710.1001/jamaoncol.2022.0615.
19. Semsar-Kazerooni K, Morand GB, Payne AE, da Silva SD, Forest VI, **Hier MP**, Pusztaszeri MP, Tamilia M, Payne RJ. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer. *J Otolaryngol Head Neck Surg.* 2022;51(1):910.1186/s40463-022-00559-9.
 20. Turkdogan S, Roy CF, Chartier G, Payne R, Mlynarek A, Forest VI, **Hier M**. Effect of Perioperative Patient Education via Animated Videos in Patients Undergoing Head and Neck Surgery: A Randomized Clinical Trial. *JAMA Otolaryngol Head Neck Surg.* 2022;148(2):173-910.1001/jamaoto.2021.3765.
 21. Zeng PYF, Cecchini MJ, Barrett JW, Shammass-Toma M, De Cecco L, Serafini MS, Cavalieri S, Licitra L, Hoebbers F, Brakenhoff RH, Leemans CR, Scheckenbach K, Poli T, Wang X, Liu X, Laxague F, Prisman E, Poh C, Bose P, Dort JC, Shaikh MH, Ryan SEB, Dawson A, Khan MI, Howlett CJ, Stecho W, Plantinga P, Daniela da Silva S, **Hier M**, Khan H, MacNeil D, Mendez A, Yoo J, Fung K, Lang P, Winquist E, Palma DA, Ziai H, Amelio AL, Li SS, Boutros PC, Mymryk JS, Nichols AC. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. *EBioMedicine.* 2022;86:10437310.1016/j.ebiom.2022.104373.

Tarek Hijal

1. Chu D, Lessard D, Laymouna MA, Engler K, Schuster T, Ma Y, Kronfli N, Routy JP, **Hijal T**, Lacombe K, Sheehan N, Rougier H, Lebouché B. Understanding the Risks and Benefits of a Patient Portal Configured for HIV Care: Patient and Healthcare Professional Perspectives. *J Pers Med.* 2022;12(2)10.3390/jpm12020314.
2. Kool R, Yanev I, **Hijal T**, Vanhuyse M, Cury FL, Souhami L, Kassouf W, Dragomir A. Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. *Can Urol Assoc J.* 2022;16(6):189-9810.5489/cuaj.7430.
3. Lessard D, Engler K, Ma Y, Rodriguez Cruz A, Vicente S, Kronfli N, Barkati S, Brouillette MJ, Cox J, Kildea J, **Hijal T**, Pomey MP, Bartlett SJ, Asselah J, Lebouché B. Remote Follow-up of Self-isolating Patients With COVID-19 Using a Patient Portal: Protocol for a Mixed Methods Pilot Study (Opal-COVID Study). *JMIR Res Protoc.* 2022;11(8):e3576010.2196/35760.

Nathalie Johnson

1. Allard D, Chrobak P, Bareche Y, Allard B, Tessier P, Bergeron MA, **Johnson NA**, Stagg J. CD73 Promotes Chronic Lymphocytic Leukemia. *Cancers (Basel).* 2022;14(13)10.3390/cancers14133130.
2. Benoit A, Bou-Petit E, Chou H, Lu M, Guilbert C, Luo VM, Assouline S, Morin RD, Dmitrienko S, Estrada-Tejedor R, **Johnson NA**, Mann KK. Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma. *Sci Rep.* 2022;12(1):77910.1038/s41598-021-04736-0.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

3. Fooks K, Galicia-Vazquez G, Gife V, Schcolnik-Cabrera A, Nouhi Z, Poon WWL, Luo V, Rys RN, Aloyz R, Orthwein A, **Johnson NA**, Hulea L, Mercier FE. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. *J Exp Clin Cancer Res.* 2022;41(1):34010.1186/s13046-022-02542-8.
4. Korsos V, Vallée A, Rys R, Probst S, Dmitrienko S, Decaluwe H, **Johnson NA**. Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab. *Leuk Lymphoma.* 2022;63(5):1256-6010.1080/10428194.2021.2012571.
5. Le-Nguyen A, Rys RN, Petrogiannis-Halioitis T, **Johnson NA**. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma. *Cancer Rep (Hoboken).* 2022;5(1):e143210.1002/cnr2.1432.
6. Preston SEJ, Emond A, Pettersson F, Dupéré-Richer D, Abraham MJ, Riva A, Kinal M, Rys RN, **Johnson NA**, Mann KK, Del Rincón SV, Licht JD, Miller WH. Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. *Mol Cancer Ther.* 2022;21(4):511-2110.1158/1535-7163.Mct-21-0216.
7. Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilén MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, **Johnson NA**, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, Thompson MA. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. *Blood Cancer Discov.* 2022;3(3):181-9310.1158/2643-3230.Bcd-22-0013.
8. Tanguay M, Boutin M, Laumaea A, Salaciak M, Mendoza A, Cassis C, Ajjamada L, Assouline S, Patenaude F, Clark MW, Finzi A, **Johnson NA**. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. *Vaccine.* 2022;40(9):1203-710.1016/j.vaccine.2022.01.040.
9. Tock WL, Maheu C, **Johnson NA**. Considerations of Control Conditions Designs in Randomized Controlled Trials of Exercise Interventions for Cancer Survivors. *Can J Nurs Res.* 2022;54(4):377-9110.1177/08445621211062467.
10. Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, **Johnson NA**, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. *Blood Adv.* 2022;6(2):590-910.1182/bloodadvances.2021004970.

Petr Kavan

1. Garant A, Vasilevsky CA, Boutros M, Khosrow-Khavar F, **Kavan P**, Diec H, Des Groseilliers S, Faria J, Ferland E, Pelsser V, Martin AG, Devic S, Vuong T. MORPHEUS Phase II-III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results. *Cancers (Basel).* 2022;14(15)10.3390/cancers14153665.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

2. Owen S, Alken S, Alshami J, Guiot MC, **Kavan P**, Reardon DA, Muanza T, Gibson N, Pemberton K, Solca F, Cseh A, Saran F. Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. *Onco Targets Ther.* 2022;15:367-8010.2147/ott.S346725.
3. Renouf DJ, Loree JM, Knox JJ, Topham JT, **Kavan P**, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko YJ, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Du P, Jia S, Schaeffer DF, Gill S, Tu D, O'Callaghan CJ. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. *Nat Commun.* 2022;13(1):502010.1038/s41467-022-32591-8.

John Kildea

1. Caissie A, Olson R, Barbera L, O'Donnell J, Davis CA, Croke J, Bird L, **Kildea J**, Brown E, Brundage M, Milosevic M. Striving to Fill in Gaps between Clinical Practice and Standards: The Evolution of a Pan-Canadian Approach to Patient-Reported Outcomes Use. *Curr Oncol.* 2022;29(5):3698-70710.3390/curroncol29050296.
2. Lessard D, Engler K, Ma Y, Rodriguez Cruz A, Vicente S, Kronfli N, Barkati S, Brouillette MJ, Cox J, **Kildea J**, Hijal T, Pomey MP, Bartlett SJ, Asselah J, Lebouché B. Remote Follow-up of Self-isolating Patients With COVID-19 Using a Patient Portal: Protocol for a Mixed Methods Pilot Study (Opal-COVID Study). *JMIR Res Protoc.* 2022;11(8):e3576010.2196/35760.
3. Naseri H, Skamene S, Tolba M, Faye MD, Ramia P, Khriugian J, Patrick H, Andrade Hernandez AX, David M, **Kildea J**. Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest. *Sci Rep.* 2022;12(1):986610.1038/s41598-022-13379-8.
4. Paterson LC, Festarini A, Stuart M, Ali F, Costello C, Boyer C, Rogge R, Ybarra N, **Kildea J**, Richardson RB. High-Accuracy Relative Biological Effectiveness Values Following Low-Dose Thermal Neutron Exposures Support Bimodal Quality Factor Response with Neutron Energy. *Int J Mol Sci.* 2022;23(2)10.3390/ijms23020878.
5. Patrick HM, **Kildea J**. Technical note: rtdsm-An open-source software for radiotherapy dose-surface map generation and analysis. *Med Phys.* 2022;49(11):7327-3510.1002/mp.15900.

Neil Kopek

1. Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthil S, Swaminath A, **Kopek N**, Liu M, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. *Int J Radiat Oncol Biol Phys.* 2022;114(4):611-610.1016/j.ijrobp.2022.05.004.
2. Ramia P, Bodgi L, Mahmoud D, Mohammad MA, Youssef B, **Kopek N**, Al-Shamsi H, Dagher M, Abu-Gheida I. Radiation-Induced Fibrosis in Patients with Head and Neck Cancer: A Review of Pathogenesis and Clinical Outcomes. *Clin Med Insights Oncol.* 2022;16:1179554921103689810.1177/11795549211036898.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Antonis Koromilas

1. **Koromilas AE**. The integrated stress response in the induction of mutant KRAS lung carcinogenesis: Mechanistic insights and therapeutic implications. *Bioessays*. 2022;44(8):e220002610.1002/bies.202200026.
2. Panda DK, Bai X, Zhang Y, Stylianesis NA, **Koromilas AE**, Lipman ML, Karaplis AC. SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis. *J Clin Invest*. 2022;132(24)10.1172/jci153943.

Pierre Laneuville

1. Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, **Laneuville P**, Lipton JH, Kamel-Reid S, Leber B. BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. *Br J Haematol*. 2022;196(1):136-4510.1111/bjh.17807.

Susie Lau

1. Abitbol J, Kucukyazici B, Brin S, **Lau S**, Salvador S, Ramanakumar AV, Kessous R, Kogan L, Fletcher JD, Pare-Miron V, Liu G, Gotlieb WH. Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer. *J Robot Surg*. 2022;10.1007/s11701-022-01447-0.
2. Gomolin A, Gotlieb W, **Lau S**, Salvador S, Racovitan F, Abitbol J. Mandate to evaluate robotic surgery implementation: a 12-year retrospective analysis of impact and future implications. *J Robot Surg*. 2022;16(4):783-810.1007/s11701-021-01327-z.
3. Kosa SD, Ferguson SE, Panzarella T, **Lau S**, Abitbol J, Samouëlian V, Giede C, Steed H, Renkosinski B, Gien LT, Bernardini MQ. A prospective comparison of costs between robotics, laparoscopy, and laparotomy in endometrial cancer among women with Class III obesity or higher. *J Surg Oncol*. 2022;125(4):747-5310.1002/jso.26769.
4. Matanes E, Amajoud Z, Salvador S, **Lau S**, Gotlieb W. Four protective maneuvers in minimal invasive surgery of endometrial cancer. *Int J Gynecol Cancer*. 2022;32(7):953-410.1136/ijgc-2021-003324.
5. Matanes E, Cantor T, AlShehri E, Salvador S, **Lau S**, Gotlieb W. Surgical technique for sentinel lymph node sampling in endometrial cancer using the articulated HOOK monopolar instrument. *Int J Gynecol Cancer*. 2022;32(7):951-210.1136/ijgc-2021-002840.
6. Matanes E, Eisenberg N, Mitric C, Yasmeen A, Ismail S, Raban O, Cantor T, Knigin D, **Lau S**, Salvador S, Gotlieb W, Kogan L. Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma. *Int J Gynecol Cancer*. 2022;32(7):875-8110.1136/ijgc-2022-003431.

Magali Lecavalier-Barsoum

1. Kasymjanova G, Rizzolo A, Pepe C, Friedmann JE, Small D, Spicer J, **Lecavalier-Barsoum M**, Sultanem K, Wang H, Spatz A, Cohen V, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol*. 2022;29(11):8677-8510.3390/currenocol29110684.
2. Matanes E, Amajoud Z, Kogan L, Mitric C, Ismail S, Raban O, Knigin D, Levin G, Bahoric B, Ferenczy A, Pelmus M, **Lecavalier-Barsoum M**, Lau S, Salvador S, Gotlieb WH. Is

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? *Gynecol Oncol.* 2023;168:107-1310.1016/j.ygyno.2022.10.023.

Ives Levesque

1. Fortier V, **Levesque IR**. Longitudinal relaxation in fat-water mixtures and its dependence on fat content at 3 T. *NMR Biomed.* 2022;35(2):e462910.1002/nbm.4629.
2. Lefebvre TL, Ueno Y, Dohan A, Chatterjee A, Vallières M, Winter-Reinhold E, Saif S, **Levesque IR**, Zeng XZ, Forghani R, Seuntjens J, Soyer P, Savadjiev P, Reinhold C. Development and Validation of Multiparametric MRI-based Radiomics Models for Preoperative Risk Stratification of Endometrial Cancer. *Radiology.* 2022;305(2):375-8610.1148/radiol.212873.

Sender Liberman

1. **GlobalSurg Collaborative and NIHR Global Health Research Unit on Global Surgery**. Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study. *Lancet Glob Health.* 2022;10(7):e1003-e1110.1016/s2214-109x(22)00168-1.
2. Al Rashid F, **Liberman AS**, Charlebois P, Stein B, Feldman LS, Fiore JF, Jr., Lee L. The impact of bowel dysfunction on health-related quality of life after rectal cancer surgery: a systematic review. *Tech Coloproctol.* 2022;26(7):515-2710.1007/s10151-022-02594-0.
3. Al-Rashid F, Robitaille S, **Liberman AS**, Charlebois P, Stein B, Feldman LS, Fiore JF, Jr., Lee L. Trajectory of change of low anterior resection syndrome over time after restorative proctectomy for rectal adenocarcinoma. *Tech Coloproctol.* 2022;26(3):195-20310.1007/s10151-021-02561-1.
4. Anpalagan T, Schmocker S, Raval M, Baxter NN, Brar MS, Easson A, Feldman LS, Lee L, **Liberman AS**, Scales DC, Kennedy ED. Home to Stay: A randomized controlled trial protocol to assess use of a mobile app to reduce readmissions following colorectal surgery. *Colorectal Dis.* 2022;24(12):1616-2110.1111/codi.16312.
5. Garfinkle R, Demian M, Sabboobeh S, Moon J, Hulme-Moir M, **Liberman AS**, Feinberg S, Hayden DM, Chadi SA, Demyttenaere S, Samuel L, Hotakorjian N, Quintin L, Morin N, Faria J, Ghitulescu G, Vasilevsky CA, Boutros M. Bowel stimulation before loop ileostomy closure to reduce postoperative ileus: a multicenter, single-blinded, randomized controlled trial. *Surg Endosc.* 2022:1-1010.1007/s00464-022-09510-5.
6. Lee L, Eustache J, Baldini G, **Liberman AS**, Charlebois P, Stein B, Fiore JF, Jr., Feldman LS. Enhanced Recovery 2.0 - Same Day Discharge With Mobile App Follow-up After Minimally Invasive Colorectal Surgery. *Ann Surg.* 2022;276(6):e812-e810.1097/sla.0000000000004962.
7. Robitaille S, Wang A, **Liberman AS**, Charlebois P, Stein B, Fiore JF, Jr., Feldman LS, Lee L. A retrospective analysis of early discharge following minimally invasive colectomy in an enhanced recovery pathway. *Surg Endosc.* 2022:1-910.1007/s00464-022-09777-8.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Carmen Loiselle

1. Ahmed S, Gotlieb WH, Erez G, **Loiselle CG**. Perceptions of BELONG as a supportive e-platform used by women with gynecologic cancers. *Psychooncology*. 2022;31(1):152-610.1002/pon.5785.
2. Ahmed S, LePage K, Benc R, Erez G, Litvin A, Werbitt A, Chartier G, Berlin C, **Loiselle CG**. Lessons Learned from the Implementation of a Person-Centred Digital Health Platform in Cancer Care. *Curr Oncol*. 2022;29(10):7171-8010.3390/currenocol29100564.
3. Ahmed S, Lévesque E, Garland R, Knoppers B, Dorval M, Simard J, Loiselle CG. Women's perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform. *Hered Cancer Clin Pract*. 2022;20(1):810.1186/s13053-022-00214-4.
4. Bourque MA, **Loiselle CG**. Patients' cancer care perceptions conceptualized through the Cancer Experience Measurement Framework. *BMC Health Serv Res*. 2022;22(1):69310.1186/s12913-022-07946-y.
5. Chênevert D, Brown TL, Pomey MP, Benomar N, Colombat P, Fouquereau E, **Loiselle CG**. Investigating a Participatory Intervention in Multidisciplinary Cancer Care Teams Using an Integrative Organizational Model: A Study Protocol. *Front Psychol*. 2022;13:79886310.3389/fpsyg.2022.798863.
6. Fitch MI, Nicoll I, Lockwood G, **Loiselle CG**, Longo CJ, Newton L, Strohschein FJ. Exploring the relationships between income and emotional/practical concerns and help-seeking by older adult cancer survivors: A secondary analysis. *J Geriatr Oncol*. 2022;13(3):337-4510.1016/j.jgo.2021.11.007.
7. Gagné M, Lauzier S, Lemay M, **Loiselle CG**, Provencher L, Simard C, Guillaumie L. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study. *Support Care Cancer*. 2022;30(6):4759-6810.1007/s00520-021-06692-x.
8. Nicoll I, Lockwood G, Longo CJ, **Loiselle CG**, Fitch MI. Relationships between Canadian adult cancer survivors' annual household income and emotional/practical concerns, help-seeking and unmet needs. *Health Soc Care Community*. 2022;30(4):e1290-e30110.1111/hsc.13536.
9. Robb A, Brown TL, Durand A, **Loiselle CG**. Cancer Survivors' Evolving Perceptions of a New Supportive Virtual Program. *Curr Oncol*. 2022;29(11):8431-4110.3390/currenocol29110664.
10. Santerre-Theil A, Brown TL, Körner A, **Loiselle CG**. Exploring healthcare professionals' experiences with informal family cancer caregiving. *Support Care Cancer*. 2022;30(9):7745-5410.1007/s00520-022-07207-y.

Richard Margolese

1. Ganz PA, Bandos H, Geyer CE, Jr., Robidoux A, Paterson AHG, Polikoff J, Baez-Diaz L, Brufsky AM, Fehrenbacher L, Parsons AW, Ward PJ, Provencher L, Hamm JT, Stella PJ, Carolla RL, **Margolese RG**, Shibata HR, Perez EA, Wolmark N. Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. *Breast Cancer Res Treat*. 2022;192(1):153-6110.1007/s10549-021-06475-2.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Luke McCaffrey

1. Catterall R, Kurdieh R, **McCaffrey L**. Studying Cell Polarity Dynamics During Cancer Initiation Using Inducible 3D Organotypic Cultures. *Methods Mol Biol.* 2022;2438:455-6610.1007/978-1-0716-2035-9_26.
2. Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, **McCaffrey L**, Deblois G, Kleinman C, Park M, Basik M, Witcher M. 3D chromatin remodeling potentiates transcriptional programs driving cell invasion. *Proc Natl Acad Sci U S A.* 2022;119(36):e220345211910.1073/pnas.2203452119

Ari Meguerditchian

1. Do U, El-Kefraoui C, Pook M, Balvardi S, Barone N, Nguyen-Powanda P, Lee L, Baldini G, Feldman LS, Fiore JF, Jr., Alhashemi M, Antoun A, Barkun JS, Brecht KM, Chaudhury PK, Deckelbaum D, Di Lena E, Dumitra S, Elhaj H, Fata P, Fleiszer D, Fried GM, Grushka J, Kaneva P, Khwaja K, Lapointe-Gagner M, McKendy KM, **Meguerditchian AN**, Meterissian SH, Montgomery H, Rajabiyazdi F, Safa N, Touma N, Tremblay F. Feasibility of Prospectively Comparing Opioid Analgesia With Opioid-Free Analgesia After Outpatient General Surgery: A Pilot Randomized Clinical Trial. *JAMA Netw Open.* 2022;5(7):e222143010.1001/jamanetworkopen.2022.21430.

David Melnychuk

1. Panet F, Tétreault-Langlois M, Morin V, Sultanem K, **Melnichuk D**, Panasci L. The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. *Cancer Rep (Hoboken).* 2022;5(7):e153110.1002/cnr.21531.

Sarkis Meterissian

1. **GlobalSurg Collaborative and NIHR Global Health Research Unit on Global Surgery.** Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study. *Lancet Glob Health.* 2022;10(7):e1003-e1110.1016/s2214-109x(22)00168-1.
2. Di Lena É, Hopkins B, Wong SM, **Meterissian S**. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study. *Surgery.* 2022;171(3):666-7210.1016/j.surg.2021.10.033.
3. Do U, El-Kefraoui C, Pook M, Balvardi S, Barone N, Nguyen-Powanda P, Lee L, Baldini G, Feldman LS, Fiore JF, Jr., Alhashemi M, Antoun A, Barkun JS, Brecht KM, Chaudhury PK, Deckelbaum D, Di Lena E, Dumitra S, Elhaj H, Fata P, Fleiszer D, Fried GM, Grushka J, Kaneva P, Khwaja K, Lapointe-Gagner M, McKendy KM, Meguerditchian AN, **Meterissian SH**, Montgomery H, Rajabiyazdi F, Safa N, Touma N, Tremblay F. Feasibility of Prospectively Comparing Opioid Analgesia With Opioid-Free Analgesia After Outpatient General Surgery: A Pilot Randomized Clinical Trial. *JAMA Netw Open.* 2022;5(7):e222143010.1001/jamanetworkopen.2022.21430.
4. Jatana S, Zahra S, Miron AD, Antonacci G, Di Lena É, Thériault M, **Meterissian S**. A retrospective study evaluating outcomes of surgical excision versus radiologic follow-up of

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- benign breast papillomas without atypia. *Am J Surg.* 2022;224(3):932-710.1016/j.amjsurg.2022.04.029.
5. Kripalani S, Kulshreshta S, Saracco B, **Meterissian S**. The effect of COVID-19 on breast cancer care and treatment in North America: A scoping review. *Am J Surg.* 2022;224(5):1222-810.1016/j.amjsurg.2022.07.015.
 6. Moldoveanu D, Ramsay L, Lajoie M, Anderson-Trocme L, Lingrand M, Berry D, Perus LJM, Wei Y, Moraes C, Alkallas R, Rajkumar S, Zuo D, Dankner M, Xu EH, Bertos NR, Najafabadi HS, Gravel S, Costantino S, Richer MJ, Lund AW, Del Rincon SV, Spatz A, Miller WH, Jr., Jamal R, Lapointe R, Mes-Masson AM, Turcotte S, Petrecca K, Dumitra S, Meguerditchian AN, Richardson K, Tremblay F, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Quail DF, Mihalcioiu C, **Meterissian S**, Watson IR. Spatially mapping the immune landscape of melanoma using imaging mass cytometry. *Sci Immunol.* 2022;7(70):eabi507210.1126/sciimmunol.abi5072.
 7. Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, **Meterissian S**, Aleynikova O, Wong N, Foulkes WD. ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol.* 2022;29(11):6671-210.1245/s10434-022-12011-3.
 8. Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, **Meterissian S**, Aleynikova O, Wong N, Foulkes WD. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol.* 2022;29(11):6660-810.1245/s10434-022-11916-3.

Nicholas Meti

1. Saleh RR, Scott JL, **Meti N**, Perlon D, Fazelzad R, Ocana A, Amir E. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. *Mol Diagn Ther.* 2022;26(2):153-6810.1007/s40291-022-00576-4.
2. Ul Haq S, Schmid S, Aparnathi MK, Hueniken K, Zhan LJ, Sacdalan D, Li JJN, **Meti N**, Patel D, Cheng D, Philip V, Tsao MS, Cabanero M, de Carvalho D, Liu G, Bratman SV, Lok BH. Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction. *iScience.* 2022;25(12):10548710.1016/j.isci.2022.105487.

Catalin Mihalcioiu

1. Hassan S, Younan R, Patocskai E, Provencher L, Poirier B, Sideris L, Dubé P, **Mihalcioiu C**, Chabot-Blanchet M, Guertin MC, Boileau JF, Robidoux A. Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec. *Oncologist.* 2022;27(10):822-3110.1093/oncolo/oyac123.
2. Li J, Camirand A, Zakikhani M, Sellin K, Guo Y, Luan X, **Mihalcioiu C**, Kremer R. Parathyroid Hormone-Related Protein Inhibition Blocks Triple-Negative Breast Cancer Expansion in Bone Through Epithelial to Mesenchymal Transition Reversal. *JBMR Plus.* 2022;6(6):e1058710.1002/jbm4.10587.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

3. Moldoveanu D, Ramsay L, Lajoie M, Anderson-Trocme L, Lingrand M, Berry D, Perus LJM, Wei Y, Moraes C, Alkallas R, Rajkumar S, Zuo D, Dankner M, Xu EH, Bertos NR, Najafabadi HS, Gravel S, Costantino S, Richer MJ, Lund AW, Del Rincon SV, Spatz A, Miller WH, Jr., Jamal R, Lapointe R, Mes-Masson AM, Turcotte S, Petrecca K, Dumitra S, Meguerditchian AN, Richardson K, Tremblay F, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Quail DF, **Mihalcioiu C**, Meterissian S, Watson IR. Spatially mapping the immune landscape of melanoma using imaging mass cytometry. *Sci Immunol*. 2022;7(70):eabi507210.1126/sciimmunol.abi5072.
4. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. *N Engl J Med*. 2022;386(1):24-34.10.1056/NEJMoa2109970.
5. Tonneau M, Nolin-Lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, Ponce M, Al-Saleh A, Belkaid W, Naimi S, **Mihalcioiu C**, Watson I, Bouin M, Miller W, Hudson M, Wong MK, Pezo RC, Turcotte S, Bélanger K, Jamal R, Oster P, Velin D, Richard C, Messaoudene M, Elkrief A, Routy B. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. *Oncoimmunology*. 2022;11(1):209653510.1080/2162402x.2022.2096535.

Wilson Miller

1. Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, **Miller WH, Jr.**, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immunotherapy. *J Immunother Cancer*. 2022;10(11)10.1136/jitc-2022-005780.
2. Conte S, Ghazawi FM, Le M, Nedjar H, Alakel A, Lagacé F, Mukovozov IM, Cyr J, Mourad A, **Miller WH, Jr.**, Claveau J, Salopek TG, Netchiporouk E, Gniadecki R, Sasseville D, Rahme E, Litvinov IV. Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada. *Front Med (Lausanne)*. 2022;9:83025410.3389/fmed.2022.830254.
3. Korsos V, **Miller WH, Jr.** How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy. *J Mol Endocrinol*. 2022;69(4):T69-t8310.1530/jme-22-0141.
4. Maio M, Amonkar MM, Norquist JM, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, **Miller WH, Jr.**, Oh DY, Gottfried M, Wang R, Norwood K, Marabelle A. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. *Eur J Cancer*. 2022;169:188-9710.1016/j.ejca.2022.03.040.
5. Maio M, Carlino MS, Joshua AM, McWhirter E, Ribas A, Ascierto PA, **Miller WH, Jr.**, Butler MO, Ferrucci PF, Zielinski RR, Del Vecchio M, Gasal E, Ghori R, Diede SJ, Croydon E, Hamid O. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. *Eur J Cancer*. 2022;160:1-1110.1016/j.ejca.2021.09.024.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

6. Malagón T, Yong JHE, Tope P, **Miller WH, Jr.**, Franco EL. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada. *Int J Cancer*. 2022;150(8):1244-5410.1002/ijc.33884.
7. Mitsa G, Guo Q, Goncalves C, Preston SEJ, Lacasse V, Aguilar-Mahecha A, Benlimame N, Basik M, Spatz A, Batist G, **Miller WH, Jr.**, Del Rincon SV, Zahedi RP, Borchers CH. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. *Int J Mol Sci*. 2022;23(8)10.3390/ijms23084443.
8. Moldoveanu D, Ramsay L, Lajoie M, Anderson-Trocme L, Lingrand M, Berry D, Perus LJM, Wei Y, Moraes C, Alkallas R, Rajkumar S, Zuo D, Dankner M, Xu EH, Bertos NR, Najafabadi HS, Gravel S, Costantino S, Richer MJ, Lund AW, Del Rincon SV, Spatz A, **Miller WH, Jr.**, Jamal R, Lapointe R, Mes-Masson AM, Turcotte S, Petrecca K, Dumitra S, Meguerditchian AN, Richardson K, Tremblay F, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Quail DF, Mihalcioiu C, Meterissian S, Watson IR. Spatially mapping the immune landscape of melanoma using imaging mass cytometry. *Sci Immunol*. 2022;7(70):eabi507210.1126/sciimmunol.abi5072.
9. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, **Miller WH, Jr.**, Safra T, Italiano A, Mileschkin L, Amonkar M, Yao L, Jin F, Norwood K, Maio M. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. *Gynecol Oncol*. 2022;166(2):245-5310.1016/j.ygyno.2022.06.005.
10. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, **Miller WH, Jr.**, Safra T, Italiano A, Mileschkin L, Xu L, Jin F, Norwood K, Maio M. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. *J Clin Oncol*. 2022;40(7):752-6110.1200/jco.21.01874.
11. Preston SEJ, Bartish M, Richard VR, Aghigh A, Gonçalves C, Smith-Voudouris J, Huang F, Thébault P, Cleret-Buhot A, Lapointe R, Légaré F, Postovit LM, Zahedi RP, Borchers CH, **Miller WH, Jr.**, Del Rincón SV. Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland. *Matrix Biol*. 2022;111:264-8810.1016/j.matbio.2022.07.003.
12. Srour N, Villarreal OD, Hardikar S, Yu Z, Preston S, **Miller WH, Jr.**, Szewczyk MM, Barsyte-Lovejoy D, Xu H, Chen T, Del Rincón SV, Richard S. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. *Cell Rep*. 2022;38(13):11058210.1016/j.celrep.2022.110582.

Thierry Muanza

1. Chaudhari P, Madaan A, Rivera JC, Charfi I, Habelrih T, Hou X, Nezhady M, Lodygensky G, Pineyro G, **Muanza T**, Chemtob S. Neuronal GPR81 regulates developmental brain angiogenesis and promotes brain recovery after a hypoxic ischemic insult. *J Cereb Blood Flow Metab*. 2022;42(7):1294-30810.1177/0271678x221077499.
2. Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, **Muanza TM**, Neal A, Olivotto IA. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. *Lancet*. 2022;400(10350):431-4010.1016/s0140-6736(22)01246-6.

3. Owen S, Alken S, Alshami J, Guiot MC, Kavan P, Reardon DA, **Muanza T**, Gibson N, Pemberton K, Solca F, Cseh A, Saran F. Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. *Onco Targets Ther*. 2022;15:367-8010.2147/ott.S346725.

Alain Nepveu

1. Vickridge E, Faraco CCF, **Nepveu A**. Base excision repair accessory factors in senescence avoidance and resistance to treatments. *Cancer Drug Resist*. 2022;5(3):703-2010.20517/cdr.2022.36.
2. Vickridge E, Faraco CCF, Tehrani PS, Ramdzan ZM, Rahimian H, Leduy L, Gingras AC, **Nepveu A**. The DNA repair function of BCL11A suppresses senescence and promotes continued proliferation of triple-negative breast cancer cells. *NAR Cancer*. 2022;4(4):zcac02810.1093/narcan/zcac028.

Tamim Niazi

1. Di Lalla V, Elakshar S, Anidjar M, Tolba M, Hassan T, Bahoric B, McPherson V, Probst S, **Niazi T**. Salvage external beam radiotherapy after HIFU failure in localized prostate cancer: A single institution experience. *Front Oncol*. 2022;12:102885810.3389/fonc.2022.1028858.
2. Di Lalla V, Kucharczyk MJ, Wyatt AW, Feng FY, Probst S, Gravis G, So J, Saad F, **Niazi T**. Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol*. 2022;81(5):437-910.1016/j.eururo.2021.12.038.
3. Kapoor A, **Niazi T**, Noonan K, Rendon RA, Alimohamed N, Kassouf W, Berlin A, Chu W, Kollmannsberger C, So AI. 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium: Meeting highlights. *Can Urol Assoc J*. 2022;16(4):125-3110.5489/cuaj.7875.
4. Malone S, Wallis CJD, Lee-Ying R, Basappa NS, Cagiannos I, Hamilton RJ, Fernandes R, Ferrario C, Gotto GT, Morgan SC, Morash C, **Niazi T**, Noonan KL, Rendon R, Hotte SJ, Saad F, Zardan A, Osborne B, Chan KFY, Shayegan B. Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study. *BJUI Compass*. 2022;3(5):383-9110.1002/bco2.158.
5. Pinthus JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, Siemens DR, **Niazi T**, Fradet V, Foster W, Duceppe E, Taussky D, Hamilton R, Lavallée L, Brown I, Chin J, Gopaul D, Wassef A, Kassouf W, Davis M, Violette PD, Agapay S, Balasubramanian K, Mian R, Rangarajan S, Sener A, Shayegan B, Devereaux PJ, Leong DP. Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy. *J Urol*. 2022;207(5):1020-810.1097/ju.0000000000002384.
6. Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, **Niazi T**, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So AI, Usmani N, Vigneault E, Chi KN. 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J*. 2022;16(11):E506-e1510.5489/cuaj.8161.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

7. Shayegan B, Wallis CJD, Hamilton RJ, Morgan SC, Cagiannos I, Basappa NS, Ferrario C, Gotto GT, Fernandes R, Roy S, Noonan KL, **Niazi T**, Hotte SJ, Saad F, Hew H, Park-Wyllie L, Chan KFY, Malone S. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. *Prostate Cancer Prostatic Dis.* 2022;10.1038/s41391-022-00514-9.
8. Shayegan B, Wallis CJD, Malone S, Cagiannos I, Hamilton RJ, Ferrario C, Gotto GT, Basappa NS, Morgan SC, Fernandes R, Morash C, **Niazi T**, Noonan KL, Rendon R, Osborne B, Park-Wyllie L, Chan KFY, Hotte SJ, Saad F. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. *Urol Oncol.* 2022;40(5):192.e1-.e910.1016/j.urolonc.2022.01.009.
9. So AI, Chi K, Danielson B, Fleshner NE, Kinnaird A, Kapoor A, **Niazi T**, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, Vigneault E, Saad F. 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naïve and castration-sensitive prostate cancer Full-text. *Can Urol Assoc J.* 2022;16(12):E581-e910.5489/cuaj.8148.
10. Tisseverasinghe S, Tolba M, Saad F, Gravis G, Bahoric B, **Niazi T**. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? *J Clin Oncol.* 2022;40(36):4173-710.1200/jco.22.00883.

Alexandre Orthwein

1. Boni J, Idani A, Roca C, Feliubadaló L, Tomiak E, Weber E, Foulkes WD, **Orthwein A**, El Haffaf Z, Lazaro C, Rivera B. A decade of RAD51C and RAD51D germline variants in cancer. *Hum Mutat.* 2022;43(3):285-9810.1002/humu.24319.
2. Dahabieh MS, Huang F, Goncalves C, Flores González RE, Prabhu S, Bolt A, Di Pietro E, Houry E, Heath J, Xu ZY, Rémy-Sarrazin J, Mann KK, **Orthwein A**, Boisvert FM, Braverman N, Miller WH, Del Rincón SV. Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance. *Autophagy.* 2022;18(3):540-5810.1080/15548627.2021.1936932.
3. Fooks K, Galicia-Vazquez G, Gife V, Schcolnik-Cabrera A, Nouhi Z, Poon WWL, Luo V, Rys RN, Aloyz R, **Orthwein A**, Johnson NA, Hulea L, Mercier FE. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. *J Exp Clin Cancer Res.* 2022;41(1):34010.1186/s13046-022-02542-8.
4. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, Djerir B, Chen X, Morin T, Lebeau B, Karam M, Bagci H, Grapton D, Ursini-Siegel J, Côté JF, Witcher M, Richard S, Maréchal A, **Orthwein A**. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep.* 2022;23(1):e5104110.15252/embr.202051041.
5. Mercier FE, Shi J, Sykes DB, Oki T, Jankovic M, Man CH, Kfoury YS, Miller E, He S, Zhu A, Vasic R, Doench J, **Orthwein A**, Michor F, Scadden DT. In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. *Blood Adv.* 2022;6(17):5072-8410.1182/bloodadvances.2022007250.
6. Sherill-Rofe D, Raban O, Findlay S, Rahat D, Unterman I, Samiei A, Yasmeen A, Kaiser Z, Kuasne H, Park M, Foulkes WD, Bloch I, Zick A, Gotlieb WH, Tabach Y, **Orthwein A**. Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. *NAR Cancer.* 2022;4(2):zcac01310.1093/narcan/zcac013.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

7. Simo Cheyou E, Boni J, Boulais J, Pinedo-Carpio E, Malina A, Sherill-Rofe D, Luo VM, Goncalves C, Bagci H, Maters A, Cuella-Martin R, Tabach Y, Del Rincon S, Côté JF, Rivera B, **Orthwein A**. Systematic proximal mapping of the classical RAD51 paralogs unravel functionally and clinically relevant interactors for genome stability. *PLoS Genet.* 2022;18(11):e101049510.1371/journal.pgen.1010495.

Scott Owen

1. **Owen S**, Alken S, Alshami J, Guiot MC, Kavan P, Reardon DA, Muanza T, Gibson N, Pemberton K, Solca F, Cseh A, Saran F. Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. *Onco Targets Ther.* 2022;15:367-8010.2147/ott.S346725.
2. Schmid S, Minnella EM, Pilon Y, Rokah M, Rayes R, Najmeh S, Cools-Lartigue J, Ferri L, Mulder D, Sirois C, **Owen S**, Shieh B, Ofiara L, Wong A, Sud S, Baldini G, Carli F, Spicer J. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care. *Clin Lung Cancer.* 2022;23(7):593-910.1016/j.clc.2022.05.004.

Lawrence Panasci

1. Panet F, Tétreault-Langlois M, Morin V, Sultanem K, Melnychuk D, **Panasci L**. The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. *Cancer Rep (Hoboken).* 2022;5(7):e153110.1002/cnr2.1531.

Valerie Panet-Raymond

1. Khriguian J, Tolba M, Khosrow-Khavar F, Kordlouie S, Guiot MC, Abdulkarim B, Shenouda G, Sirhan D, Souhami L, **Panet-Raymond V**. Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas? *Can J Neurol Sci.* 2022;1-710.1017/cjn.2022.28.
2. Nowakowski A, Lahijanian Z, **Panet-Raymond V**, Siegel PM, Petrecca K, Maleki F, Dankner M. Radiomics as an emerging tool in the management of brain metastases. *Neurooncol Adv.* 2022;4(1):vdac14110.1093/noajnl/vdac141.

Morag Park

1. Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, **Park M**, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. *Oncogene.* 2022;41(12):1701-1710.1038/s41388-022-02206-z.
2. Brewer G, Fortier AM, **Park M**, Moraes C. The case for cancer-associated fibroblasts: essential elements in cancer drug discovery? *Future Drug Discov.* 2022;4(1):Fdd7110.4155/fdd-2021-0004.
3. Coelho PP, Hesketh GG, Pedersen A, Kuzmin E, Fortier AN, Bell ES, Ratcliffe CDH, Gingras AC, **Park M**. Endosomal LC3C-pathway selectively targets plasma membrane cargo for autophagic degradation. *Nat Commun.* 2022;13(1):381210.1038/s41467-022-31465-3.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

4. Coelho PP, **Park M**. LEAP: a novel LC3C-dependent pathway connects autophagy, endocytic trafficking and signaling. *Autophagy*. 2022;1-310.1080/15548627.2022.2117973.
5. Elkholi IE, Lalonde A, **Park M**, Côté JF. Breast Cancer Metastatic Dormancy and Relapse: An Enigma of Microenvironment(s). *Cancer Res*. 2022;82(24):4497-51010.1158/0008-5472.Can-22-1902.
6. Gómez-Cuadrado L, Bullock E, Mabruk Z, Zhao H, Souleimanova M, Noer PR, Turnbull AK, Oxvig C, Bertos N, Byron A, Dixon JM, **Park M**, Haider S, Natrajan R, Sims AH, Brunton VG. Characterisation of the Stromal Microenvironment in Lobular Breast Cancer. *Cancers (Basel)*. 2022;14(4)10.3390/cancers14040904.
7. Kay EJ, Paterson K, Riera-Domingo C, Sumpton D, Däbritz JHM, Tardito S, Boldrini C, Hernandez-Fernaund JR, Athineos D, Dhayade S, Stepanova E, Gjerga E, Neilson LJ, Lilla S, Hedley A, Koulouras G, McGregor G, Jamieson C, Johnson RM, **Park M**, Kirschner K, Miller C, Kamphorst JJ, Loayza-Puch F, Saez-Rodriguez J, Mazzone M, Blyth K, Zagnoni M, Zanivan S. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. *Nat Metab*. 2022;4(6):693-71010.1038/s42255-022-00582-0.
8. Kay EJ, Paterson K, Riera-Domingo C, Sumpton D, Däbritz JHM, Tardito S, Boldrini C, Hernandez-Fernaund JR, Athineos D, Dhayade S, Stepanova E, Gjerga E, Neilson LJ, Lilla S, Hedley A, Koulouras G, McGregor G, Jamieson C, Johnson RM, **Park M**, Kirschner K, Miller C, Kamphorst JJ, Loayza-Puch F, Saez-Rodriguez J, Mazzone M, Blyth K, Zagnoni M, Zanivan S. Author Correction: Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. *Nat Metab*. 2022;4(8):108410.1038/s42255-022-00632-7.
9. Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, **Park M**, Basik M, Witcher M. 3D chromatin remodeling potentiates transcriptional programs driving cell invasion. *Proc Natl Acad Sci U S A*. 2022;119(36):e220345211910.1073/pnas.2203452119.
10. Pathmanathan S, Yao Z, Coelho P, Valla R, Drecun L, Benz C, Snider J, Saraon P, Grozavu I, Kotlyar M, Jurisica I, **Park M**, Stagljar I. B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. *iScience*. 2022;25(11):10541910.1016/j.isci.2022.105419.
11. Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, Vandekerere A, Cuadros AM, Fernández-García J, Riera-Domingo C, Jauset C, Planque M, Alkan HF, Nittner D, Zuo D, Broadfield LA, Parik S, Pane AA, Rizzollo F, Rinaldi G, Zhang T, Teoh ST, Aurora AB, Karras P, Vermeire I, Broekaert D, Elsen JV, Knott MML, Orth MF, Demeyer S, Eelen G, Dobrolecki LE, Bassez A, Brussel TV, Sotlar K, Lewis MT, Bartsch H, Wuhrer M, Veelen PV, Carmeliet P, Cools J, Morrison SJ, Marine JC, Lambrechts D, Mazzone M, Hannon GJ, Lunt SY, Grünewald TGP, **Park M**, Rheenen JV, Fendt SM. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. *Nature*. 2022;605(7911):747-5310.1038/s41586-022-04758-2.
12. Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, Vandekerere A, Cuadros AM, Fernández-García J, Riera-Domingo C, Jauset C, Planque M, Alkan HF, Nittner D, Zuo D, Broadfield LA, Parik S, Pane AA, Rizzollo F, Rinaldi G, Zhang T, Teoh ST, Aurora AB, Karras P, Vermeire I, Broekaert D, Elsen JV, Knott MML, Orth MF,

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- Demeyer S, Eelen G, Dobrolecki LE, Bassez A, Brussel TV, Sotlar K, Lewis MT, Bartsch H, Wuhrer M, Veelen PV, Carmeliet P, Cools J, Morrison SJ, Marine JC, Lambrechts D, Mazzone M, Hannon GJ, Lunt SY, Grünewald TGP, **Park M**, Rheenen JV, Fendt SM. Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. *Nature*. 2022;609(7927):E810.1038/s41586-022-05226-7.
13. Sherill-Rofe D, Raban O, Findlay S, Rahat D, Unterman I, Samiei A, Yasmeen A, Kaiser Z, Kuasne H, **Park M**, Foulkes WD, Bloch I, Zick A, Gotlieb WH, Tabach Y, Orthwein A. Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. *NAR Cancer*. 2022;4(2):zcac01310.1093/narcan/zcac013.
 14. Stern YE, Al-Ghabkari A, Monast A, Fiset B, Aboualizadeh F, Yao Z, Stagljar I, Walsh LA, Duhamel S, **Park M**. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells. *Cell Mol Life Sci*. 2022;79(3):17810.1007/s00018-022-04149-w.
 15. Wu J, Liu X, Reeser JAW, Trimboli AJ, Pécot T, Sizemore GM, Naidu SK, Fernandez SA, Yu L, Hallett M, **Park M**, Leone GW, Hildreth BE, Ostrowski MC. Stromal p53 Regulates Breast Cancer Development, the Immune Landscape, and Survival in an Oncogene-Specific Manner. *Mol Cancer Res*. 2022;20(8):1233-4610.1158/1541-7786.Mcr-21-0960.

François Patenaude

1. Tanguay M, Boutin M, Laumaea A, Salaciak M, Mendoza A, Cassis C, Ajjamada L, Assouline S, **Patenaude F**, Clark MW, Finzi A, Johnson NA. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. *Vaccine*. 2022;40(9):1203-710.1016/j.vaccine.2022.01.040.
2. Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DY, Hansen AR, Graham J, Soulières D, Reaume MN, Lalani AA, Castonguay V, Bjarnason GA, **Patenaude F**, Breau RH, Pouliot F, Kapoor A, Wood LA. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. *Clin Genitourin Cancer*. 2022;20(3):210-810.1016/j.clgc.2021.12.003.

Horacio Patrocinio

1. Khriguian J, **Patrocinio H**, Andonian S, Aprikian A, Kassouf W, Tanguay S, Cury FL. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. *Pract Radiat Oncol*. 2022;12(1):e34-e910.1016/j.ppro.2021.07.006.

Jerry Pelletier

1. Girgis S, Xu Z, Oikonomopoulos S, Fedorova AD, Tchesnokov EP, Gordon CJ, Schmeing TM, Götte M, Sonenberg N, Baranov PV, Ragoussis J, Hobman TC, **Pelletier J**. Evolution of naturally arising SARS-CoV-2 defective interfering particles. *Commun Biol*. 2022;5(1):114010.1038/s42003-022-04058-5.
2. Lehman SL, Wechsler T, Schwartz K, Brown LE, Porco JA, Devine WG, **Pelletier J**, Shankavaram UT, Camphausen K, Tofilon PJ. Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity. *Mol Cancer Ther*. 2022;21(9):1406-1410.1158/1535-7163.Mct-22-0037.
3. Naineni SK, Robert F, Nagar B, **Pelletier J**. Targeting DEAD-box RNA helicases: The emergence of molecular staples. *Wiley Interdiscip Rev RNA*. 2022:e173810.1002/wrna.1738.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

4. Xu Z, Choi JH, Dai DL, Luo J, Ladak RJ, Li Q, Wang Y, Zhang C, Wiebe S, Liu ACH, Ran X, Yang J, Naeli P, Garzia A, Zhou L, Mahmood N, Deng Q, Elaish M, Lin R, Mahal LK, Hobman TC, **Pelletier J**, Alain T, Vidal SM, Duchaine T, Mazhab-Jafari MT, Mao X, Jafarnejad SM, Sonenberg N. SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation. *Proc Natl Acad Sci U S A*. 2022;119(32):e220453911910.1073/pnas.2204539119.

Carmela Pepe

1. Agulnik JS, Papadakis AI, **Pepe C**, Sakr L, Small D, Wang H, Kasymjanova G, Spatz A, Cohen V. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). *Curr Oncol*. 2022;29(2):1107-1610.3390/curroncol29020094.
2. Kasymjanova G, Rizzolo A, **Pepe C**, Friedmann JE, Small D, Spicer J, Lecavalier-Barsoum M, Sultanem K, Wang H, Spatz A, Cohen V, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol*. 2022;29(11):8677-8510.3390/curroncol29110684.

Samara Perez

1. Griffin-Mathieu G, Haward B, Tatar O, Zhu P, **Perez S**, Shapiro GK, McBride E, Thompson EL, Smith LW, Lofters AK, Daley EM, Guichon JR, Waller J, Steben M, Decker KM, Mayrand MH, Brotherton JML, Ogilvie GS, Zimet GD, Norris T, Rosberger Z. Ensuring a Successful Transition From Cytology to Human Papillomavirus-Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Women's Intentions: Protocol for an Observational Study. *JMIR Res Protoc*. 2022;11(6):e3891710.2196/38917.
2. Haward B, Tatar O, Zhu P, Griffin-Mathieu G, **Perez S**, Shapiro GK, McBride E, Zimet GD, Rosberger Z. Development and validation of the cervical cancer knowledge scale and HPV testing knowledge scale in a sample of Canadian women. *Prev Med Rep*. 2022;30:10201710.1016/j.pmedr.2022.102017.
3. Tatar O, Haward B, Zhu P, Griffin-Mathieu G, **Perez S**, Zimet G, Rosberger Z. Using Best-Worst Scaling to investigate younger adult Canadians' preferences for COVID-19 vaccination and public health measures: An observational study. *Prev Med Rep*. 2022;26:10175510.1016/j.pmedr.2022.101755.
4. Zhu P, Tatar O, Griffin-Mathieu G, **Perez S**, Haward B, Zimet G, Tunis M, Dubé È, Rosberger Z. The Efficacy of a Brief, Altruism-Eliciting Video Intervention in Enhancing COVID-19 Vaccination Intentions Among a Population-Based Sample of Younger Adults: Randomized Controlled Trial. *JMIR Public Health Surveill*. 2022;8(5):e3732810.2196/37328.
5. Zhu P, Tatar O, Haward B, Griffin-Mathieu G, **Perez S**, Smith L, Brotherton J, Ogilvie G, Rosberger Z. Assessing Canadian women's preferences for cervical cancer screening: A brief report. *Front Public Health*. 2022;10:96203910.3389/fpubh.2022.962039.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Alan Peterson

1. Liu H, Grouza V, Tuznik M, Siminovitch KA, Bagheri H, **Peterson A**, Rudko DA. Self-labelled encoder-decoder (SLED) for multi-echo gradient echo-based myelin water imaging. *Neuroimage*. 2022;264:11971710.1016/j.neuroimage.2022.119717.

Michael Pollak

1. Broadfield LA, Saigal A, Szamosi JC, Hammill JA, Bezverbnaya K, Wang D, Gautam J, Tsakiridis EE, Di Pastena F, McNicol J, Wu J, Syed S, Lally JSV, Raphenya AR, Blouin MJ, **Pollak M**, Sacconi A, Blandino G, McArthur AG, Schertzer JD, Surette MG, Collins SM, Bramson JL, Muti P, Tsakiridis T, Steinberg GR. Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. *Mol Metab*. 2022;61:10149810.1016/j.molmet.2022.101498.
2. Campbell PT, Newton CC, Jacobs EJ, McCullough ML, Wang Y, Rees-Punia E, Ginter MA, Murphy N, Koshiol J, Dehal AN, Rohan T, Strickler H, Petrick J, Gunter M, Zhang X, McGlynn KA, **Pollak M**, Patel AV, Gapstur SM. Prospective associations of hemoglobin A(1c) and c-peptide with risk of diabetes-related cancers in the Cancer Prevention Study-II Nutrition Cohort. *Cancer Res Commun*. 2022;2(7):653-6210.1158/2767-9764.crc-22-0082.
3. Chau CH, Till C, Price DK, Goodman PJ, Neuhaus ML, **Pollak MN**, Thompson IM, Figg WD. Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. *Endocr Relat Cancer*. 2022;29(2):99-10910.1530/erc-21-0107.
4. DuBois RN, **Pollak MN**. Introducing Cancer Center Director Perspectives on Prevention. *Cancer Prev Res (Phila)*. 2022;15(11):713-410.1158/1940-6207.Capr-22-0425.
5. Eisenberg ER, Weiss A, Prakash I, Skamene S, Basik M, Boileau JF, Ajjamada L, **Pollak MN**, Wong SM. Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. *Ann Surg Oncol*. 2022;29(11):6673-8010.1245/s10434-022-11947-w.
6. Ma C, Wang Y, Wilson KM, Mucci LA, Stampfer MJ, **Pollak M**, Penney KL. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. *JNCI Cancer Spectr*. 2022;6(1)10.1093/jncics/pkab091.
7. Parisotto M, Vuong-Robillard N, Kalegari P, Meharwade T, Joumier L, Igelmann S, Bourdeau V, Rowell MC, **Pollak M**, Malleshiah M, Schmitzer A, Ferbeyre G. The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. *Cancers (Basel)*. 2022;14(22)10.3390/cancers14225597.
8. Uchenunu O, Zhdanov AV, Hutton P, Jovanovic P, Wang Y, Andreev DE, Hulea L, Papadopoli DJ, Avizonis D, Baranov PV, **Pollak MN**, Papkovsky DB, Topisirovic I. Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells. *FEBS Open Bio*. 2022;12(5):959-8210.1002/2211-5463.13398.
9. Wang Y, Gapstur SM, Newton CC, McCullough ML, **Pollak MN**, Campbell PT. Biomarkers of Glucose Homeostasis and Inflammation with Risk of Prostate Cancer: A Case-Cohort Study. *Cancer Epidemiol Biomarkers Prev*. 2022;31(4):736-4310.1158/1055-9965.Epi-21-1060.
10. Wong SM, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, **Pollak MN**, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer*. 2022;128(7):1365-7210.1002/cncr.34065.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

11. Yazdanpanah N, Yazdanpanah M, Wang Y, Forgetta V, **Pollak M**, Polychronakos C, Richards JB, Manousaki D. Clinically Relevant Circulating Protein Biomarkers for Type 1 Diabetes: Evidence From a Two-Sample Mendelian Randomization Study. *Diabetes Care*. 2022;45(1):169-7710.2337/dc21-1049.

Ipshita Prakash

1. Eisenberg ER, Weiss A, **Prakash I**, Skamene S, Basik M, Boileau JF, Ajjamada L, Pollak MN, Wong SM. Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. *Ann Surg Oncol*. 2022;29(11):6673-8010.1245/s10434-022-11947-w.
2. **Prakash I**, Neely NB, Thomas SM, Sammons S, Blitzblau RC, DiLalla GA, Hyslop T, Menendez CS, Plichta JK, Rosenberger LH, Fayanju OM, Hwang ES, Greenup RA. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. *Cancer Med*. 2022;11(4):1099-10810.1002/cam4.4517.
3. Wong SM, Ajjamada L, Weiss AC, **Prakash I**, Skamene S, Boileau JF, Pollak MN, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer*. 2022;128(7):1365-7210.1002/cncr.34065.
4. Wong SM, Ferroum A, Apostolova C, Alhassan B, **Prakash I**, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD. ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol*. 2022;29(11):6671-210.1245/s10434-022-12011-3.
5. Wong SM, Ferroum A, Apostolova C, Alhassan B, **Prakash I**, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol*. 2022;29(11):6660-810.1245/s10434-022-11916-3.

Raghu Rajan

1. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, **Rajan R**, Aprikian A, Tanguay S, Cury FL, Brimo F, Souhami L, Kassouf W. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci*. 2022;36:26-3310.1016/j.euros.2021.11.011.

Paul Ramia

1. Abou Heidar N, El-Doueihi R, Merhe A, **Ramia P**, Bustros G, Yacoubian A, Jaafar R, Nasr R. The role of pre-biopsy mpMRI in lymph node staging for prostate cancer. *Urologia*. 2022;89(1):64-910.1177/03915603211016805.
2. Naseri H, Skamene S, Tolba M, Faye MD, **Ramia P**, Khriuguian J, Patrick H, Andrade Hernandez AX, David M, Kildea J. Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest. *Sci Rep*. 2022;12(1):986610.1038/s41598-022-13379-8.
3. **Ramia P**, Bodgi L, Mahmoud D, Mohammad MA, Youssef B, Kopek N, Al-Shamsi H, Dagher M, Abu-Gheida I. Radiation-Induced Fibrosis in Patients with Head and Neck

Gerald Bronfman Department of Oncology Annual Report 2022 Publications

Cancer: A Review of Pathogenesis and Clinical Outcomes. *Clin Med Insights Oncol.* 2022;16:1179554921103689810.1177/11795549211036898.

Stéphane Richard

1. Dominici C, **Richard S**. Muscle stem cell polarity requires QKI-mediated alternative splicing of Integrin Alpha-7 (Itga7). *Life Sci Alliance.* 2022;5(5)10.26508/lsa.202101192.
2. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, Djerir B, Chen X, Morin T, Lebeau B, Karam M, Bagci H, Grapton D, Ursini-Siegel J, Côté JF, Witcher M, **Richard S**, Maréchal A, Orthwein A. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep.* 2022;23(1):e5104110.15252/embr.202051041.
3. Lee J, Villarreal OD, Wang YC, Ragoussis J, Rivest S, Gosselin D, **Richard S**. PRMT1 is required for the generation of MHC-associated microglia and remyelination in the central nervous system. *Life Sci Alliance.* 2022;5(10)10.26508/lsa.202201467.
4. Lee JS, Lamarche-Vane N, **Richard S**. Microexon alternative splicing of small GTPase regulators: Implication in central nervous system diseases. *Wiley Interdiscip Rev RNA.* 2022;13(2):e167810.1002/wrna.1678.
5. Mersaoui SY, Guilbert C, Chou H, Douillet C, Bohle DS, Stýblo M, **Richard S**, Mann KK. Arsenic 3 methyltransferase (AS3MT) automethylates on cysteine residues in vitro. *Arch Toxicol.* 2022;96(5):1371-8610.1007/s00204-022-03248-8.
6. Srouf N, Khan S, **Richard S**. The Influence of Arginine Methylation in Immunity and Inflammation. *J Inflamm Res.* 2022;15:2939-5810.2147/jir.S364190.
7. Srouf N, **Richard S**. Putting introns on retainer. *Nat Chem Biol.* 2022;18(8):795-610.1038/s41589-022-01025-3.
8. Srouf N, Villarreal OD, Hardikar S, Yu Z, Preston S, Miller WH, Jr., Szewczyk MM, Barsyte-Lovejoy D, Xu H, Chen T, Del Rincón SV, **Richard S**. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. *Cell Rep.* 2022;38(13):11058210.1016/j.celrep.2022.110582.

Stephen Robbins

1. Lau A, Rahn JJ, Chappellaz M, Chung H, Benediktsson H, Bihan D, von Mässenhausen A, Linkermann A, Jenne CN, **Robbins SM**, Senger DL, Lewis IA, Chun J, Muruve DA. Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. *Sci Adv.* 2022;8(5):eabm014210.1126/sciadv.abm0142.

Zeev Rosberger

1. Albert JG, Lo C, **Rosberger Z**, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Sultanem K, Shenouda G, Cury FL, Henry M. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol.* 2022;29(7):4438-5410.3390/currenconcol29070353.
2. Gelgoot EN, Kruglova K, Chan P, Lo K, **Rosberger Z**, Chown P, Kazdan J, O'Connell SBL, Zelkowitz P. Evaluation of a Mobile Health App Offering Fertility Information to Male Patients With Cancer: Usability Study. *JMIR Cancer.* 2022;8(2):e3359410.2196/33594.
3. Griffin-Mathieu G, Haward B, Tatar O, Zhu P, Perez S, Shapiro GK, McBride E, Thompson EL, Smith LW, Lofters AK, Daley EM, Guichon JR, Waller J, Steben M, Decker KM,

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

- Mayrand MH, Brotherton JML, Ogilvie GS, Zimet GD, Norris T, **Rosberger Z**. Ensuring a Successful Transition From Cytology to Human Papillomavirus-Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Women's Intentions: Protocol for an Observational Study. *JMIR Res Protoc*. 2022;11(6):e3891710.2196/38917.
4. Haward B, Tatar O, Zhu P, Griffin-Mathieu G, Perez S, Shapiro GK, McBride E, Zimet GD, **Rosberger Z**. Development and validation of the cervical cancer knowledge scale and HPV testing knowledge scale in a sample of Canadian women. *Prev Med Rep*. 2022;30:10201710.1016/j.pmedr.2022.102017.
 5. Henry M, Albert JG, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Lo C, **Rosberger Z**. Body Image Concerns in Patients With Head and Neck Cancer: A Longitudinal Study. *Front Psychol*. 2022;13:81658710.3389/fpsyg.2022.816587.
 6. Henry M, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, **Rosberger Z**. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology*. 2022;31(2):185-9710.1002/pon.5803.
 7. Miner SA, Gelgoot EN, Lahuec A, Wunderlich S, Safo D, Brochu F, Dawadi S, Robins S, Bernadette S, O'Connell L, Chan P, Ells C, Holzer H, Lo K, Mahutte N, Ouhilal S, **Rosberger Z**, Tulandi T, Zelkowitz P. "Who needs an app? Fertility patients' use of a novel mobile health app". *Digit Health*. 2022;8:2055207622110224810.1177/20552076221102248.
 8. Shapiro GK, Tatar O, Knäuper B, Griffin-Mathieu G, **Rosberger Z**. The impact of publicly funded immunization programs on human papillomavirus vaccination in boys and girls: An observational study. *Lancet Reg Health Am*. 2022;8:10012810.1016/j.lana.2021.100128.
 9. Tatar O, Haward B, Zhu P, Griffin-Mathieu G, Perez S, Zimet G, **Rosberger Z**. Using Best-Worst Scaling to investigate younger adult Canadians' preferences for COVID-19 vaccination and public health measures: An observational study. *Prev Med Rep*. 2022;26:10175510.1016/j.pmedr.2022.101755.
 10. Zhu P, Tatar O, Griffin-Mathieu G, Perez S, Haward B, Zimet G, Tunis M, Dubé È, **Rosberger Z**. The Efficacy of a Brief, Altruism-Eliciting Video Intervention in Enhancing COVID-19 Vaccination Intentions Among a Population-Based Sample of Younger Adults: Randomized Controlled Trial. *JMIR Public Health Surveill*. 2022;8(5):e3732810.2196/37328.
 11. Zhu P, Tatar O, Haward B, Griffin-Mathieu G, Perez S, Smith L, Brotherton J, Ogilvie G, **Rosberger Z**. Assessing Canadian women's preferences for cervical cancer screening: A brief report. *Front Public Health*. 2022;10:96203910.3389/fpubh.2022.962039.

April Rose

1. Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, **Rose AAN**, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. *Oncogene*. 2022;41(12):1701-1710.1038/s41388-022-02206-z.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

2. Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, **Rose AAN**. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. *JCO Precis Oncol.* 2022;6:e220010710.1200/po.22.00107.
3. Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, **Rose AAN**, Siegel PM, Watson IR. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. *Cell Rep.* 2022;39(1):11063410.1016/j.celrep.2022.110634.
4. Rodriguez-Ramirez S, Yau K, Kitchlu A, John R, **Rose AAN**, Hogg D, Kim SJ. Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report. *Kidney Med.* 2022;4(5):10046110.1016/j.xkme.2022.100461.
5. Soria-Bretones I, Thu KL, Silvester J, Cruickshank J, El Ghamrasni S, Ba-Alawi W, Fletcher GC, Kiarash R, Elliott MJ, Chalmers JJ, Elia AC, Cheng A, **Rose AAN**, Bray MR, Haibe-Kains B, Mak TW, Cescon DW. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER(+) breast cancer with mitotic aberrations. *Sci Adv.* 2022;8(36):eabq429310.1126/sciadv.abq4293.

Nader Sadeghi

1. Albert JG, Lo C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, **Sadeghi N**, Sultanem K, Shenouda G, Cury FL, Henry M. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol.* 2022;29(7):4438-5410.3390/currenconcol29070353.
2. Arif R, Marzouki HZ, Silver JA, Al Thomali R, Merdad M, **Sadeghi N**. Primary prevention of depression in head and neck cancer patients: a scoping review. *Eur Arch Otorhinolaryngol.* 202210.1007/s00405-022-07783-z.
3. Henry M, Albert JG, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, **Sadeghi N**, Lo C, Rosberger Z. Body Image Concerns in Patients With Head and Neck Cancer: A Longitudinal Study. *Front Psychol.* 2022;13:81658710.3389/fpsyg.2022.816587.
4. Henry M, Arnovitz E, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, **Sadeghi N**, Rosberger Z. Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. *Psychooncology.* 2022;31(2):185-9710.1002/pon.5803.
5. Lee E, Crowder HR, Gorelik D, Badger C, Schottler J, Li NW, Siegel R, **Sadeghi N**, Thakkar PG, Joshi AS, Goodman JF. Comparison of quality of life outcomes in a de-intensification treatment regimen for p16+ oropharyngeal cancer. *Eur Arch Otorhinolaryngol.* 2022;279(9):4533-4010.1007/s00405-022-07387-7.
6. Lee E, Gorelik D, Crowder HR, Badger C, Schottler J, Li NW, Siegel R, **Sadeghi N**, Goodman JF, Thakkar PG, Joshi AS. Swallowing Function Following Neoadjuvant

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Carcinoma: A 2-Year Follow-up. *Otolaryngol Head Neck Surg.* 2022;167(2):298-30410.1177/01945998211057430.
7. Mascarella MA, Muthukrishnan N, Maleki F, Kergoat MJ, Richardson K, Mlynarek A, Forest VI, Reinhold C, Martin DR, Hier M, **Sadeghi N**, Forghani R. Above and Beyond Age: Prediction of Major Postoperative Adverse Events in Head and Neck Surgery. *Ann Otol Rhinol Laryngol.* 2022;131(7):697-70310.1177/00034894211041222.
 8. Mohtashami S, Richardson K, Forest VI, Mlynarek A, Payne RJ, Tamilia M, Pusztaszeri MP, Hier MP, **Sadeghi N**, Mascarella MA. Thyroidectomy for Graves' Disease Predicts Postoperative Neck Hematoma and Hypocalcemia: A North American cohort study. *Ann Otol Rhinol Laryngol.* 2022;131(4):341-5110.1177/00034894211021288.
 9. Moya-Garcia CR, Okuyama H, **Sadeghi N**, Li J, Tabrizian M, Li-Jessen NYK. In vitro models for head and neck cancer: Current status and future perspective. *Front Oncol.* 2022;12:96034010.3389/fonc.2022.960340.
 10. Silver JA, Turkdogan S, Roy CF, Subramaniam T, Henry M, **Sadeghi N**. De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma-Where Are We Now? *Curr Oncol.* 2022;29(5):3668-9710.3390/currenconcol29050295.

Ramy Saleh

1. Hu J, Aprikian AG, **Saleh RR**, Dragomir A. Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. *Curr Oncol.* 2022;29(11):8626-3710.3390/currenconcol29110680.
2. **Saleh RR**, Scott JL, Meti N, Perlon D, Fazelzad R, Ocana A, Amir E. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. *Mol Diagn Ther.* 2022;26(2):153-6810.1007/s40291-022-00576-4.

Donna Senger

1. Lau A, Rahn JJ, Chappellaz M, Chung H, Benediktsson H, Bihan D, von Mässenhausen A, Linkermann A, Jenne CN, Robbins SM, **Senger DL**, Lewis IA, Chun J, Muruve DA. Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. *Sci Adv.* 2022;8(5):eabm014210.1126/sciadv.abm0142.

George Shenouda

1. Albert JG, Lo C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, Sultanem K, **Shenouda G**, Cury FL, Henry M. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol.* 2022;29(7):4438-5410.3390/currenconcol29070353.
2. Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, **Shenouda G**, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. *Head Neck.* 2022;44(1):158-6710.1002/hed.26915.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

3. Caudell JJ, Torres-Saavedra PA, Rosenthal DI, Axelrod RS, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, El-Naggar AK, Konski AA, Echevarria MI, Dunlap NE, **Shenouda G**, Singh AK, Beitler JJ, Garsa A, Bonner JA, Garden AS, Algan O, Harris J, Le QT. Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer. *Int J Radiat Oncol Biol Phys.* 2022;10.1016/j.ijrobp.2022.12.015.
4. Dhillon J, Li DQ, Burnier M, **Shenouda G**, Arthurs BP, El-Hadad C. Cemiplimab for metastatic squamous cell carcinoma of the orbit, periocular adnexa, and thigh. *Orbit.* 2022;1-710.1080/01676830.2022.2118789.
5. Khriouian J, Tolba M, Khosrow-Khavar F, Kordlouie S, Guiot MC, Abdulkarim B, **Shenouda G**, Sirhan D, Souhami L, Panet-Raymond V. Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas? *Can J Neurol Sci.* 2022;1-710.1017/cjn.2022.28.

Chaim Shustik

1. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, **Shustik C**, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. *J Clin Oncol.* 2022;40(1):52-6210.1200/jco.21.00838.
2. Cornell RF, Baz R, Richter JR, Rossi A, Vogl DT, Chen C, **Shustik C**, Alvarez MJ, Shen Y, Unger TJ, Ben-Shahar O, Wang H, Baloglu E, Senapedis W, Ma X, Landesman Y, Bai X, Bader J, Xu H, Marshall T, Chang H, Walker CJ, Shah J, Shacham S, Kauffman MG, Hofmeister CC. A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. *Am J Hematol.* 2022;97(2):E54-e810.1002/ajh.26420.

Shireen Sirhan

1. Szuber N, Toliopoulos P, Busque L, Cerquozzi S, Foltz L, Gupta V, Tefferi A, Vannucchi AM, Hillis C, Leber B, Maze D, Prchal J, Olney HJ, **Sirhan S**. Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion. *Am J Hematol.* 2022;97(12):E466-e910.1002/ajh.26739.

Sonia Skamene

1. Eisenberg ER, Weiss A, Prakash I, **Skamene S**, Basik M, Boileau JF, Ajjamada L, Pollak MN, Wong SM. Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. *Ann Surg Oncol.* 2022;29(11):6673-8010.1245/s10434-022-11947-w.
2. Naseri H, **Skamene S**, Tolba M, Faye MD, Ramia P, Khriouian J, Patrick H, Andrade Hernandez AX, David M, Kildea J. Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest. *Sci Rep.* 2022;12(1):986610.1038/s41598-022-13379-8.
3. Wong SM, Ajjamada L, Weiss AC, Prakash I, **Skamene S**, Boileau JF, Pollak MN, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer.* 2022;128(7):1365-7210.1002/cncr.34065.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Luis Souhami

1. Almarzouq A, Kool R, Al Bulushi Y, Marcq G, **Souhami L**, Cury FL, Brimo F, Chong J, Kassouf W. Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. *Urol Oncol.* 2022;40(5):194.e15-.e2210.1016/j.urolonc.2021.11.002.
2. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. *NPJ Digit Med.* 2022;5(1):7110.1038/s41746-022-00613-w.
3. Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, **Souhami L**, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. *Int J Radiat Oncol Biol Phys.* 2022;112(1):83-9210.1016/j.ijrobp.2021.07.004.
4. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, **Souhami L**, Michalski JM, Hartford AC, Amin PP, Roach M, 3rd, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. *Int J Radiat Oncol Biol Phys.* 2022;112(2):294-30310.1016/j.ijrobp.2021.08.031.
5. Khriguian J, Tolba M, Khosrow-Khavar F, Kordlouie S, Guiot MC, Abdulkarim B, Shenouda G, Sirhan D, **Souhami L**, Panet-Raymond V. Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas? *Can J Neurol Sci.* 2022;1-710.1017/cjn.2022.28.
6. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, **Souhami L**, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. *Lancet Oncol.* 2022;23(2):304-1610.1016/s1470-2045(21)00705-1.
7. Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, **Souhami L**, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, Spratt DE. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. *Eur Urol.* 2022;82(1):106-1410.1016/j.eururo.2022.04.003.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

8. Kool R, Marcq G, Shinde-Jadhav S, Mansure JJ, Saleh R, Rajan R, Aprikian A, Tanguay S, Cury FL, Brimo F, **Souhami L**, Kassouf W. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. *Eur Urol Open Sci.* 2022;36:26-3310.1016/j.euros.2021.11.011.
9. Kool R, Yanev I, Hijal T, Vanhuysse M, Cury FL, **Souhami L**, Kassouf W, Dragomir A. Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. *Can Urol Assoc J.* 2022;16(6):189-9810.5489/cuaj.7430.
10. Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, **Souhami L**, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. *J Clin Oncol.* 2022;40(23):2539-4510.1200/jco.21.02543.
11. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M, 3rd, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, **Souhami L**, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, Spratt DE, Kishan AU. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). *Eur Urol.* 2022;82(5):487-9810.1016/j.eururo.2022.07.011.
12. Marcq G, Evaristo G, Kool R, Shinde-Jadhav S, Skowronski R, Mansure JJ, **Souhami L**, Cury F, Brimo F, Kassouf W. Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. *Eur Urol Open Sci.* 2022;43:14-2110.1016/j.euros.2022.06.009.
13. Nabid A, **Souhami L**. Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. *Eur J Cancer.* 2022;167:166-710.1016/j.ejca.2022.01.042.

Alan Spatz

1. Agulnik JS, Papadakis AI, Pepe C, Sakr L, Small D, Wang H, Kasymjanova G, **Spatz A**, Cohen V. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). *Curr Oncol.* 2022;29(2):1107-1610.3390/curroncol29020094.
2. Kasymjanova G, Rizzolo A, Pepe C, Friedmann JE, Small D, Spicer J, Lecavalier-Barsoum M, Sultanem K, Wang H, **Spatz A**, Cohen V, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol.* 2022;29(11):8677-8510.3390/curroncol29110684.
3. Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Filip E, Taberero J, Batist G, **Spatz A**, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. *JCO Precis Oncol.* 2022;6:e220007210.1200/po.22.00072.

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

4. Li JH, Forghani R, Bure L, Wojtkiewicz GR, Wu Y, Iwamoto Y, Ali M, Li A, Wang C, Jalali Motlagh N, Papadakis AI, Pusztaszeri MP, **Spatz A**, Curtin H, Cheng YS, Chen JW. Molecular immuno-imaging improves tumor detection in head and neck cancer. *Faseb j*. 2022;36(1):e2209210.1096/fj.202100864R.
5. Mitsa G, Guo Q, Goncalves C, Preston SEJ, Lacasse V, Aguilar-Mahecha A, Benlimame N, Basik M, **Spatz A**, Batist G, Miller WH, Jr., Del Rincon SV, Zahedi RP, Borchers CH. A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. *Int J Mol Sci*. 2022;23(8)10.3390/ijms23084443.
6. Moldoveanu D, Ramsay L, Lajoie M, Anderson-Trocme L, Lingrand M, Berry D, Perus LJM, Wei Y, Moraes C, Alkallas R, Rajkumar S, Zuo D, Dankner M, Xu EH, Bertos NR, Najafabadi HS, Gravel S, Costantino S, Richer MJ, Lund AW, Del Rincon SV, **Spatz A**, Miller WH, Jr., Jamal R, Lapointe R, Mes-Masson AM, Turcotte S, Petrecca K, Dumitra S, Meguerditchian AN, Richardson K, Tremblay F, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Quail DF, Mihalcioiu C, Meterissian S, Watson IR. Spatially mapping the immune landscape of melanoma using imaging mass cytometry. *Sci Immunol*. 2022;7(70):eabi507210.1126/sciimmunol.abi5072.
7. Selvarajah S, Schrader KA, Kolinsky MP, Rendon RA, El Hallani S, Fleshner NE, Hotte SJ, Lorentz J, Panabaker K, Perrier R, Pouliot F, **Spatz A**, Yip S, Chi KN. Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada. *Can Urol Assoc J*. 2022;16(10):321-3210.5489/cuaj.7954.
8. Yu HG, Bijian K, da Silva SD, Su J, Morand G, **Spatz A**, Alaoui-Jamali MA. NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation. *Oncogene*. 2022;41(21):2984-9910.1038/s41388-022-02317-7.

Barry Stein

1. Lee L, Eustache J, Baldini G, Liberman AS, Charlebois P, **Stein B**, Fiore JF, Jr., Feldman LS. Enhanced Recovery 2.0 - Same Day Discharge With Mobile App Follow-up After Minimally Invasive Colorectal Surgery. *Ann Surg*. 2022;276(6):e812-e810.1097/sla.0000000000004962.
2. Leung V, Baldini G, Liberman S, Charlebois P, **Stein B**, Fiore JF, Jr., Feldman LS, Lee L. Trajectory of gastrointestinal function after laparoscopic colorectal surgery within an enhanced recovery pathway. *Surgery*. 2022;171(3):607-1410.1016/j.surg.2021.08.062.
3. Leung VWY, Baldini G, Liberman S, Charlebois P, **Stein B**, Feldman LS, Fiore JF, Jr., Lee L. Tolerating clear fluids diet on postoperative day 0 predicts early recovery of gastrointestinal function after laparoscopic colectomy. *Surg Endosc*. 2022;36(12):9262-7210.1007/s00464-022-09151-8.
4. Robitaille S, Wang A, Liberman AS, Charlebois P, **Stein B**, Fiore JF, Jr., Feldman LS, Lee L. A retrospective analysis of early discharge following minimally invasive colectomy in an enhanced recovery pathway. *Surg Endosc*. 2022:1-910.1007/s00464-022-09777-8.

Shelly Sud

1. Schmid S, Minnella EM, Pilon Y, Rokah M, Rayes R, Najmeh S, Cools-Lartigue J, Ferri L, Mulder D, Sirois C, Owen S, Shieh B, Ofiara L, Wong A, **Sud S**, Baldini G, Carli F, Spicer J. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

Cancer: Optimizing Outcomes Throughout the Trajectory of Care. *Clin Lung Cancer*. 2022;23(7):593-910.1016/j.clc.2022.05.004.

Khalil Sultanem

1. Albert JG, Lo C, Rosberger Z, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Mascarella M, Morand GB, Chartier G, Sadeghi N, **Sultanem K**, Shenouda G, Cury FL, Henry M. Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study. *Curr Oncol*. 2022;29(7):4438-5410.3390/curroncol29070353.
2. Cherba M, Brummans B, Hier MP, Giguère L, Chartier G, Jacobs H, Forest VI, Mlynarek A, **Sultanem K**, Henry M. Framing Concerns about Body Image during Pre- and Post-Surgical Consultations for Head and Neck Cancer: A Qualitative Study of Patient-Physician Interactions. *Curr Oncol*. 2022;29(5):3341-6310.3390/curroncol29050272.
3. Kasymjanova G, Rizzolo A, Pepe C, Friedmann JE, Small D, Spicer J, Lecavalier-Barsoum M, **Sultanem K**, Wang H, Spatz A, Cohen V, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. *Curr Oncol*. 2022;29(11):8677-8510.3390/curroncol29110684.
4. Morand GB, **Sultanem K**, Mascarella MA, Hier MP, Mlynarek AM. Historical Perspective: How the Discovery of HPV Virus Led to the Utilization of a Robot. *Front Oral Health*. 2022;3:91286110.3389/froh.2022.912861.
5. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, **Sultanem K**, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Odell M, Parker C, Wehrli B, Kwan K, Palma DA. Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial. *J Clin Oncol*. 2022;40(8):866-7510.1200/jco.21.01961.
6. Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, **Sultanem K**, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial. *JAMA Oncol*. 2022;8(6):1-710.1001/jamaoncol.2022.0615.
7. Panet F, Tétreault-Langlois M, Morin V, **Sultanem K**, Melnychuk D, Panasci L. The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. *Cancer Rep (Hoboken)*. 2022;5(7):e153110.1002/cnr2.1531.
8. Subramaniam RM, DeMora L, Yao M, Yom SS, Gillison M, Caudell JJ, Waldron J, Xia P, Chung C, Truong MT, Echevarria M, Chan JW, Geiger JL, Mell L, Seaward S, Thorstad WL, Beitler JJ, **Sultanem K**, Blakaj D, Le QT. (18)F FDG PET/CT Prediction of Treatment Outcomes in HPV-positive, Locally Advanced Oropharyngeal Cancer Receiving De-intensified Therapy: Results from NRG-HN002. *J Nucl Med*. 2022;10.2967/jnumed.122.264424.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Steven Tisseverasinghe

1. **Tisseverasinghe S**, Tolba M, Saad F, Gravis G, Bahoric B, Niazi T. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? *J Clin Oncol.* 2022;40(36):4173-710.1200/jco.22.00883.

Ivan Topisirovic

1. Abdullah MO, Zeng RX, Margerum CL, Papadopoli D, Monnin C, Punter KB, Chu C, Al-Rofaidi M, Al-Tannak NF, Berardi D, Rattray Z, Rattray NJW, Abraham SA, Eskelinen EL, Watson DG, Avizonis D, **Topisirovic I**, Chan EYW. Mitochondrial hyperfusion via metabolic sensing of regulatory amino acids. *Cell Rep.* 2022;40(7):11119810.1016/j.celrep.2022.111198.
2. Feng Y, Grotegut S, Jovanovic P, Gandin V, Olson SH, Murad R, Beall A, Colayco S, De-Jesus P, Chanda S, English BP, Singer RH, Jackson M, **Topisirovic I**, Ronai ZA. Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex. *Front Pharmacol.* 2022;13:102909310.3389/fphar.2022.1029093.
3. Katsumura S, Siddiqui N, Goldsmith MR, Cheah JH, Fujikawa T, Minegishi G, Yamagata A, Yabuki Y, Kobayashi K, Shirouzu M, Inagaki T, Huang TH, Musi N, **Topisirovic I**, Larsson O, Morita M. Deadenylation-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure. *Cell Metab.* 2022;34(4):564-80.e810.1016/j.cmet.2022.03.005.
4. Krokowski D, Jobava R, Szkop KJ, Chen CW, Fu X, Venus S, Guan BJ, Wu J, Gao Z, Banaszuk W, Tchorzewski M, Mu T, Ropelewski P, Merrick WC, Mao Y, Sevval AI, Miranda H, Qian SB, Manifava M, Ktistakis NT, Vourekas A, Jankowsky E, **Topisirovic I**, Larsson O, Hatzoglou M. Stress-induced perturbations in intracellular amino acids reprogram mRNA translation in osmoadaptation independently of the ISR. *Cell Rep.* 2022;40(3):11109210.1016/j.celrep.2022.111092.
5. Kusnadi EP, Timpone C, **Topisirovic I**, Larsson O, Furic L. Regulation of gene expression via translational buffering. *Biochim Biophys Acta Mol Cell Res.* 2022;1869(1):11914010.1016/j.bbamcr.2021.119140.
6. Lazar I, Fabre B, Feng Y, Khateb A, Frit P, Kashina A, Zhang T, Avitan-Hersh E, Kim H, Brown K, **Topisirovic I**, Ronai ZA. Arginyl-tRNA-protein transferase 1 (ATE1) promotes melanoma cell growth and migration. *FEBS Lett.* 2022;596(11):1468-8010.1002/1873-3468.14376.
7. Tseng HW, Mota-Sydor A, Leventis R, Jovanovic P, **Topisirovic I**, Duchaine TF. Distinct, opposing functions for CFIm59 and CFIm68 in mRNA alternative polyadenylation of Pten and in the PI3K/Akt signalling cascade. *Nucleic Acids Res.* 2022;50(16):9397-41210.1093/nar/gkac704.
8. Uchenunu O, Zhdanov AV, Hutton P, Jovanovic P, Wang Y, Andreev DE, Hulea L, Papadopoli DJ, Avizonis D, Baranov PV, Pollak MN, Papkovsky DB, **Topisirovic I**. Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells. *FEBS Open Bio.* 2022;12(5):959-8210.1002/2211-5463.13398.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Anna Towers

1. McNeely ML, Harris SR, Dolgoy ND, Al Onazi MM, Parkinson JF, Radke L, Kostaras X, Dennett L, Ryan JA, Dalzell MA, Kennedy A, Capozzi L, **Towers A**, Campbell KL, Binkley J, King K, Keast D. Update to the Canadian clinical practice guideline for best-practice management of breast cancer-related lymphedema: study protocol. *CMAJ Open*. 2022;10(2):E338-e4710.9778/cmajo.20210038.

Michel Tremblay

1. Coulis G, Londhe AD, Sagabala RS, Shi Y, Labbé DP, Bergeron A, Sahadevan P, Nawaito SA, Sahmi F, Josse M, Vinette V, Guertin MC, Karsenty G, **Tremblay ML**, Tardif JC, Allen BG, Boivin B. Protein tyrosine phosphatase 1B regulates miR-208b-argonaute 2 association and thyroid hormone responsiveness in cardiac hypertrophy. *Sci Signal*. 2022;15(730):eabn687510.1126/scisignal.abn6875.
2. Fillier TA, Shah S, Doody KM, Pham TH, Aubry I, **Tremblay ML**, Cheema SK, Blundell J, Thomas RH. Brief exposure of neuronal cells to levels of SCFAs observed in human systemic circulation impair lipid metabolism resulting in apoptosis. *Sci Rep*. 2022;12(1):1435510.1038/s41598-022-18363-w.
3. González-Recio I, Simón J, Goikoetxea-Usandizaga N, Serrano-Maciá M, Mercado-Gómez M, Rodríguez-Agudo R, Lachiondo-Ortega S, Gil-Pitarch C, Fernández-Rodríguez C, Castellana D, Latasa MU, Abecia L, Anguita J, Delgado TC, Iruzubieta P, Crespo J, Hardy S, Petrov PD, Jover R, Avila MA, Martín C, Schaeper U, **Tremblay ML**, Dear JW, Masson S, McCain MV, Reeves HL, Andrade RJ, Lucena MI, Buccella D, Martínez-Cruz LA, Martínez-Chantar ML. Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage. *Nat Commun*. 2022;13(1):681610.1038/s41467-022-34262-0.
4. Papaioannou A, Centonze F, Metais A, Maurel M, Negroni L, Gonzalez-Quiroz M, Mahdizadeh SJ, Svensson G, Zare E, Blondel A, Koong AC, Hetz C, Pedoux R, **Tremblay ML**, Eriksson LA, Chevet E. Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs. *Life Sci Alliance*. 2022;5(5)10.26508/lsa.202201379.
5. Poirier A, **Tremblay ML**. Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy. *Cancer Immunol Immunother*. 202210.1007/s00262-022-03333-y.
6. Spalinger MR, Shawki A, Chatterjee P, Canale V, Santos A, Sayoc-Becerra A, Scharl M, **Tremblay ML**, Borneman J, McCole DF. Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence. *Gut*. 2022;71(1):89-9910.1136/gutjnl-2020-323636.

Francine Tremblay

1. Do U, El-Kefraoui C, Pook M, Balvardi S, Barone N, Nguyen-Powanda P, Lee L, Baldini G, Feldman LS, Fiore JF, Jr., Alhashemi M, Antoun A, Barkun JS, Brecht KM, Chaudhury PK, Deckelbaum D, Di Lena E, Dumitra S, Elhaj H, Fata P, Fleiszer D, Fried GM, Grushka J, Kaneva P, Khwaja K, Lapointe-Gagner M, McKendy KM, Meguerditchian AN, Meterissian SH, Montgomery H, Rajabiyazdi F, Safa N, Touma N, **Tremblay F**. Feasibility of Prospectively Comparing Opioid Analgesia With Opioid-Free Analgesia After Outpatient General Surgery: A Pilot Randomized Clinical Trial. *JAMA Netw Open*. 2022;5(7):e222143010.1001/jamanetworkopen.2022.21430.

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

2. Moldoveanu D, Ramsay L, Lajoie M, Anderson-Trocme L, Lingrand M, Berry D, Perus LJM, Wei Y, Moraes C, Alkallas R, Rajkumar S, Zuo D, Dankner M, Xu EH, Bertos NR, Najafabadi HS, Gravel S, Costantino S, Richer MJ, Lund AW, Del Rincon SV, Spatz A, Miller WH, Jr., Jamal R, Lapointe R, Mes-Masson AM, Turcotte S, Petrecca K, Dumitra S, Meguerditchian AN, Richardson K, **Tremblay F**, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Quail DF, Mihalcioiu C, Meterissian S, Watson IR. Spatially mapping the immune landscape of melanoma using imaging mass cytometry. *Sci Immunol.* 2022;7(70):eabi507210.1126/sciimmunol.abi5072.

Christina Tsien

1. Leeper HE, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley ME, Hervey-Jumper S, Miaskowski C, Sherwood P, **Tsien C**, Wallgren K, Willmarth N, Arons D, Acquaye A, King AL, Penas-Prado M, Vera E, Gilbert MR, Armstrong TS. Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT). *Neurooncol Adv.* 2022;4(1):vdac02910.1093/noonl/vdac029.

Josie Ursini-Siegel

1. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, Djerir B, Chen X, Morin T, Lebeau B, Karam M, Bagci H, Grapton D, **Ursini-Siegel J**, Côté JF, Witcher M, Richard S, Maréchal A, Orthwein A. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep.* 2022;23(1):e5104110.15252/embr.202051041.

Carol-Ann Vasilevsky

1. Auer RC, Ott M, Karanicolas P, Brackstone MR, Ashamalla S, Weaver J, Tagalakis V, Boutros M, Stotland P, Marulanda AC, Moloo H, Jayaraman S, Patel S, Le Gal G, Spadafora S, MacLellan S, Trottier D, Jonker D, Asmis T, Mallick R, Pecarskie A, Ramsay T, Carrier M. Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. *Bmj.* 2022;378:e07137510.1136/bmj-2022-071375.
2. Garant A, **Vasilevsky CA**, Boutros M, Khosrow-Khavar F, Kavan P, Diec H, Des Groseilliers S, Faria J, Ferland E, Pelsser V, Martin AG, Devic S, Vuong T. MORPHEUS Phase II-III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results. *Cancers (Basel).* 2022;14(15)10.3390/cancers14153665.
3. Garfinkle R, Dell'Aniello S, Bhatnagar S, Morin N, Ghitulescu G, Faria J, **Vasilevsky CA**, Brassard P, Boutros M. Assessment of long-term bowel dysfunction after restorative proctectomy for neoplastic disease: A population-based cohort study. *Surgery.* 2022;172(3):782-810.1016/j.surg.2021.10.068.
4. Garfinkle R, Demian M, Sabboobeh S, Moon J, Hulme-Moir M, Liberman AS, Feinberg S, Hayden DM, Chadi SA, Demyttenaere S, Samuel L, Hotakorzian N, Quintin L, Morin N, Faria J, Ghitulescu G, **Vasilevsky CA**, Boutros M. Bowel stimulation before loop ileostomy closure to reduce postoperative ileus: a multicenter, single-blinded, randomized controlled trial. *Surg Endosc.* 2022:1-1010.1007/s00464-022-09510-5.
5. Garfinkle R, Salama E, Amar-Zifkin A, Morin N, Ghitulescu G, Faria J, **Vasilevsky CA**, Boutros M. Observational versus antibiotic therapy for acute uncomplicated diverticulitis:

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- A non-inferiority meta-analysis based on a Delphi consensus. *Surgery*. 2022;171(2):328-3510.1016/j.surg.2021.07.012.
6. Holland J, Cwintal M, Rigas G, Pang AJ, **Vasilevsky CA**, Morin N, Ghitulescu G, Faria J, Boutros M. The impact of delaying colonoscopies during the COVID-19 pandemic on colorectal cancer detection and prevention. *Surg Endosc*. 2022;36(12):9364-7310.1007/s00464-022-09211-z.
 7. Moon J, Pang A, Ghitulescu G, Faria J, Morin N, **Vasilevsky CA**, Boutros M. Early discharge after colorectal cancer resection: trends and impact on patient outcomes. *Surg Endosc*. 2022;36(9):6617-2810.1007/s00464-021-08923-y.
 8. Pang A, **Vasilevsky CA**. Reply. *Dis Colon Rectum*. 2022;10.1097/dcr.0000000000002697.
 9. Pang AJ, Harra Z, Chen L, Morin NA, Faria JJ, Ghitulescu GA, Boutros M, **Vasilevsky CA**. Understanding the Burden of Colorectal Adenomas in Patients Younger Than 50 Years: A Large Single-Center Retrospective Cohort Study. *Dis Colon Rectum*. 2022;65(7):901-810.1097/dcr.0000000000002069.
 10. Pang AJ, Marinescu D, Morin N, **Vasilevsky CA**, Boutros M. Segmental resection of splenic flexure colon cancers provides an adequate lymph node harvest and is a safe operative approach - an analysis of the ACS-NSQIP database. *Surg Endosc*. 2022;36(8):5652-910.1007/s00464-021-08926-9.
 11. Salama E, Al-Rashid F, Pang A, Ghitulescu G, **Vasilevsky CA**, Boutros M. Oral Antibiotic Bowel Preparation Prior to Urgent Colectomy Reduces Odds of Organ Space Surgical Site Infections: a NSQIP Propensity-Score Matched Study. *J Gastrointest Surg*. 2022;26(10):2193-20010.1007/s11605-022-05440-8.

Antonio Vigano

1. Hachem Y, Abdallah SJ, Rueda S, Wiese JL, Mehra K, Rup J, Cowan J, **Vigano A**, Costiniuk CT. Healthcare practitioner perceptions on barriers impacting cannabis prescribing practices. *BMC Complement Med Ther*. 2022;22(1):23710.1186/s12906-022-03716-9.
2. Hendriks S, Huisman MG, Ghignone F, **Vigano A**, de Liguori Carino N, Farinella E, Girocchi R, Audisio RA, van Munster B, de Bock GH, van Leeuwen BL. Timed up and go test and long-term survival in older adults after oncologic surgery. *BMC Geriatr*. 2022;22(1):93410.1186/s12877-022-03585-4.
3. Kasvis P, Canac-Marquis M, Aprikian S, Vigano M, **Vigano A**. Sex differences exist in the perceived relief of cancer symptoms with medical cannabis: results from the Quebec Cannabis Registry. *Support Care Cancer*. 2022;30(10):7863-7110.1007/s00520-022-07193-1.
4. Mboumba Bouassa RS, Needham J, Nohynek D, Singer J, Lee T, Bobeuf F, Samarani S, Del Balso L, Paisible N, Vertzagias C, Sebastiani G, Margolese S, Mandarino E, Klein M, Lebouché B, Cox J, Brouillette MJ, Routy JP, Szabo J, Thomas R, Huchet E, **Vigano A**, Jenabian MA, Costiniuk CT. Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028). *Biomedicines*. 2022;10(12)10.3390/biomedicines10123168.
5. Sotoodeh R, Waldman LE, **Vigano A**, Moride Y, Canac-Marquis M, Spilak T, Gamaoun R, Kalaba M, Hachem Y, Beaulieu P, Desroches J, Ware MA, Perez J, Shir Y, Fitzcharles MA, Martel MO. Predictors of Pain Reduction Among Fibromyalgia Patients Using Medical

**Gerald Bronfman Department of Oncology Annual Report 2022
Publications**

Cannabis: A Long-Term Prospective Cohort Study. *Arthritis Care Res (Hoboken)*. 2022;10.1002/acr.24985.

6. **Vigano A**, Moride Y, Hachem Y, Canac-Marquis M, Gamaoun R, Kalaba M, Martel MO, Perez J, Néron A, Beaulieu P, Desroches J, Ware M. The Quebec Cannabis Registry: Investigating the Safety and Effectiveness of Medical Cannabis. *Cannabis Cannabinoid Res*. 2022;10.1089/can.2022.0041.

Té Vuong

1. Garant A, Vasilevsky CA, Boutros M, Khosrow-Khavar F, Kavan P, Diec H, Des Groseilliers S, Faria J, Ferland E, Pelsser V, Martin AG, Devic S, **Vuong T**. MORPHEUS Phase II-III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results. *Cancers (Basel)*. 2022;14(15)10.3390/cancers14153665.
2. Gerard JP, Myint AS, Barbet N, Dejean C, Thamphya B, Gal J, Montagne L, **Vuong T**. Targeted Radiotherapy Using Contact X-ray Brachytherapy 50 kV. *Cancers (Basel)*. 2022;14(5)10.3390/cancers14051313.
3. Stewart AJ, Van Limbergen EJ, Gerard JP, Appelt AL, Verhaegen F, Berbee M, **Vuong T**, Brooker C, Rockall T, Sun Myint A. GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. *Clin Transl Radiat Oncol*. 2022;33:15-22. 10.1016/j.ctro.2021.12.004.
4. **Vuong T**, Garant A, Vendrely V, Nout R, Martin AG, Enger SA, Podgorsak E, Moftah B, Devic S. Image-Guided Brachytherapy for Rectal Cancer: Reviewing the Past Two Decades of Clinical Investigation. *Cancers (Basel)*. 2022;14(19)10.3390/cancers14194846.

Michael Witcher

1. Heath J, Cheyou ES, Findlay S, Luo VM, Carpio EP, Lee J, Djerir B, Chen X, Morin T, Lebeau B, Karam M, Bagci H, Grapton D, Ursini-Siegel J, Côté JF, **Witcher M**, Richard S, Maréchal A, Orthwein A. POGZ promotes homology-directed DNA repair in an HP1-dependent manner. *EMBO Rep*. 2022;23(1):e51041. 10.15252/embr.202051041.
2. Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, Park M, Basik M, **Witcher M**. 3D chromatin remodeling potentiates transcriptional programs driving cell invasion. *Proc Natl Acad Sci U S A*. 2022;119(36):e2203452119. 10.1073/pnas.2203452119.
3. Lebeau B, Zhao K, Jangal M, Zhao T, Guerra M, Greenwood CMT, **Witcher M**. Single base-pair resolution analysis of DNA binding motif with MoMotif reveals an oncogenic function of CTCF zinc-finger 1 mutation. *Nucleic Acids Res*. 2022;50(15):8441-58. 10.1093/nar/gkac658.

Stephanie Wong

1. Di Lena É, Hopkins B, **Wong SM**, Meterissian S. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study. *Surgery*. 2022;171(3):666-72. 10.1016/j.surg.2021.10.033.
2. Eisenberg ER, Weiss A, Prakash I, Skamene S, Basik M, Boileau JF, Ajjamada L, Pollak MN, **Wong SM**. Surgical Management and Contralateral Breast Cancer Risk in Women

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. *Ann Surg Oncol.* 2022;29(11):6673-8010.1245/s10434-022-11947-w.
3. Ferroum A, **Wong SM**. ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy. *Ann Surg Oncol.* 2022;29(11):6669-7010.1245/s10434-022-12013-1.
 4. **Wong SM**, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, Pollak MN, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer.* 2022;128(7):1365-7210.1002/cncr.34065.
 5. **Wong SM**, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD. ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol.* 2022;29(11):6671-210.1245/s10434-022-12011-3.
 6. **Wong SM**, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated? *Ann Surg Oncol.* 2022;29(11):6660-810.1245/s10434-022-11916-3.

Norma Ybarra

1. Paterson LC, Festarini A, Stuart M, Ali F, Costello C, Boyer C, Rogge R, **Ybarra N**, Kildea J, Richardson RB. High-Accuracy Relative Biological Effectiveness Values Following Low-Dose Thermal Neutron Exposures Support Bimodal Quality Factor Response with Neutron Energy. *Int J Mol Sci.* 2022;23(2)10.3390/ijms23020878.

George Zogopoulos

1. Alghamdi A, Palmieri V, Alotaibi N, Barkun A, **Zogopoulos G**, Chaudhury P, Barkun J, Miller C, Benmassaoud A, Parent J, Martel M, Chen YI. Preoperative Endoscopic Ultrasound Fine Needle Aspiration Versus Upfront Surgery in Resectable Pancreatic Cancer: A Systematic Review and Meta-analysis of Clinical Outcomes Including Survival and Risk of Tumor Recurrence. *J Can Assoc Gastroenterol.* 2022;5(3):121-810.1093/jcag/gwab037.
2. Chen YI, Chatterjee A, Berger R, Kanber Y, Wyse J, Lam E, Gan I, Auger M, Kenshil S, Telford J, Donnellan F, Quinlan J, Lutzak G, Alshamsi F, Parent J, Waschke K, Alghamdi A, Barkun J, Metrakos P, Chaudhury P, Martel M, Dorreen A, Candido K, Miller C, Adam V, Barkun A, **Zogopoulos G**, Wong C. Endoscopic ultrasound (EUS)-guided fine needle biopsy alone vs. EUS-guided fine needle aspiration with rapid onsite evaluation in pancreatic lesions: a multicenter randomized trial. *Endoscopy.* 2022;54(1):4-1210.1055/a-1375-9775.
3. Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, **Zogopoulos G**, Rose AAN. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies

Gerald Bronfman Department of Oncology Annual Report 2022
Publications

- in Patients With Non-V600 BRAF-Mutant Tumors. *JCO Precis Oncol.* 2022;6:e220010710.1200/po.22.00107.
4. Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, Domecq C, Bourdel G, Denroche RE, Jang GH, Grant RC, Borgida A, Grünwald BT, Dodd A, Wilson JM, Bourque G, O'Kane GM, Fischer SE, Kron CM, Fiset PO, Omeroglu A, Foulkes WD, Gallinger S, Guiot MC, Gao ZH, **Zogopoulos G**. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. *Front Oncol.* 2022;12:86076710.3389/fonc.2022.860767.
 5. Gonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, Saunders M, Siddiqui UD, Brand R, Simeone DM. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the **Pancreatic Cancer Early Detection Consortium**. *Gastrointest Endosc.* 2022;95(4):723-32.e710.1016/j.gie.2021.10.025.
 6. O'Kane GM, Grünwald BT, Jang GH, Masoomian M, Picardo S, Grant RC, Denroche RE, Zhang A, Wang Y, Miller JK, Lam B, Krzyzanowski PM, Lungu IM, Bartlett JMS, Peralta M, Vyas F, Khokha R, Biagi J, Chadwick D, Ramotar S, Hutchinson S, Dodd A, Wilson JM, Notta F, **Zogopoulos G**, Gallinger S, Knox JJ, Fischer SE. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. *Clin Cancer Res.* 2022;28(12):271510.1158/1078-0432.Ccr-22-1272.
 7. Perera S, Jang GH, Wang Y, Kelly D, Allen M, Zhang A, Denroche RE, Dodd A, Ramotar S, Hutchinson S, Tehfe M, Ramjeesingh R, Biagi J, Lam B, Wilson J, Fischer SE, **Zogopoulos G**, Notta F, Gallinger S, Grant RC, Knox JJ, O'Kane GM. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res.* 2022;28(23):5115-2010.1158/1078-0432.Ccr-22-2576.
 8. Wang Y, Cuggia A, Chen YI, Parent J, Stanek A, Denroche RE, Zhang A, Grant RC, Domecq C, Golesworthy B, Shwaartz C, Borgida A, Holter S, Wilson JM, Chong G, O'Kane GM, Knox JJ, Fischer SE, Gallinger S, Gao ZH, Foulkes WD, Waschke KA, **Zogopoulos G**. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? *J Natl Compr Canc Netw.* 2022;20(6):663-73.e1210.6004/jnccn.2021.7107.
 9. Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, **Zogopoulos G**. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. *J Med Genet.* 2022;59(8):793-80010.1136/jmedgenet-2021-108054.